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Abstract
The occurrence of drug-drug-interactions (DDI) from multiple drug dispensations is a serious problem,
both for individuals and health-care systems, since patients with complications due to DDI are likely to
reenter the system at a costlier level. We present a large-scale longitudinal study (18 months) of the
DDI phenomenon at the primary- and secondary-care level using electronic health records (EHR) from
the city of Blumenau in Southern Brazil (pop. ≈ 340, 000). We found that 181 distinct drug pairs known
to interact were dispensed concomitantly to 12% of the patients in the city’s public health-care system.
Further, 4% of the patients were dispensed drug pairs that are likely to result in major adverse drug
reactions (ADR)—with costs estimated to be much larger than previously reported in smaller studies.
The large-scale analysis reveals that women have a 60% increased risk of DDI as compared to men;
the increase becomes 90% when considering only DDI known to lead to major ADR. Furthermore, DDI
risk increases substantially with age; patients aged 70-79 years have a 34% risk of DDI when they are
dispensed two or more drugs concomitantly. Interestingly, a statistical null model demonstrates that age-
and female-specific risks from increased polypharmacy fail by far to explain the observed DDI risks in those
populations, suggesting unknown social or biological causes. We also provide a network visualization of
drugs and demographic factors that characterize the DDI phenomenon and demonstrate that accurate
DDI prediction can be included in healthcare and public-health management, to reduce DDI-related ADR
and costs.
keywords: drug-drug interactions, public-health, electronic health records, digital medicine, computational
intelligence, network science, machine learning.
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1 Introduction
Adverse drug reactions (ADR) from drug-drug interactions (DDI) is a well-known public health problem
worldwide [1–3]. Most efforts to measure the scale of ADR from DDI focus on hospitalizations and emergency
visits [4–10] or literature meta-analysis [3, 11, 12]. Very few studies so far have been able to characterize
this problem in primary and secondary care settings. Lack of access to longitudinal data from Electronic
Health Records (EHR) of large populations continues to be the main barrier to measuring the prevalence of
DDI and characterizing the phenomenon in medical care [13–15]. For instance, Molden et al [16] searched
43,500 patients in pharmacy databases in southeastern Norway, studying only DDI from CYP inhibitor-
substrate drugs. Pinto et al [17] studied DDI prevalence in a small cohort of forty elderly hypertensive
patients in a primary health care unit in Brazil. Iyer et al [18] mined 50 million clinical notes from the
private EHR database STRIDE [19], to identify signals of unknown potential DDI from clinical text. While
STRIDE contains EHR from multiple care levels, this analysis did not address the concomitant dispensation
of pairs of drugs with known DDI in primary- and secondary-care. Lastly, Guthrie et al [20] performed a
repeated cross-sectional comparison of 84 days in 1995 and 2010, to study the increase in polypharmacy and
DDI at the primary- and secondary-care level in the Tayside region of Scotland (pop. 405,721); DDI was
defined according to the British National Formulary, a private publication. This study estimated that 13%
of adults (≥ 20 y.o.) were prescribed a “potentially serious” known DDI in 2010, and that the number of
drugs prescribed was the characteristic most predictive of DDI. Patients prescribed 15 or more drugs had
an almost 27 fold DDI risk increase over those prescribed two to four drugs. However, by using only 84-day
windows, this analysis misses potential co-administrations from separate prescriptions made outside of the
relatively short windows; it also analyzed prescription, rather than dispensation data.
Here we pursue a large-scale longitudinal study of the DDI phenomenon at the primary- and secondary-
care levels in an entire city, using considerably larger time-windows and relying on public DDI and ADR
standards. We obtained 18 months of EHR data for the city of Blumenau in Southern Brazil (pop. 338,876),
a city with a very high Human Development Index (HDI=0.806 [21])—at the level of the top quartile of
countries according to this United Nations Development Programme index [22]. Brazil has a universal public
health-care system, and Blumenau possesses a city-wide Health Information System (HIS) with prescription
and dispensation information for its entire population. The analysis of Blumenau’s EHR data is thus an
opportunity to understand the DDI phenomenon in a highly developed city in a country where DDI is known
to occur similarly to other nations [10, 11]. The study provides an understanding of both prevalence and
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bias in the dispensation of known DDI outside of hospital settings. Dispensation data is only a surrogate for
administration of DDI, as we are not certain that patients actually take the medications that are dispensed
concomitantly. However, dispensation data can only be a better surrogate of administration than prescription
data that was used in previous studies (e.g.[20]), as a prescription may ultimately not be dispensed.
From a public-health perspective, the concomitant administration of drugs with adverse interactions is
of great concern [5, 10, 11]. Since over 30% of all ADR are thought to be caused by DDI [18], better
identification and prediction of administration of known DDI in primary- and secondary-care could reduce
the number of patients seeking urgent care in hospitals, resulting in substantial savings for health systems
worldwide [3, 7, 14]. A systematic review from 2009 showed that the proportion of hospital inpatients with
ADR (in general, not DDI only) ranged from 1.6 to 41.4% [11]. Furthermore, an estimated 52% (45%) of
ADR in outpatients (inpatients) were preventable [12]. In the elderly population alone (> 65 y.o.), the yearly
financial burden of ADR was estimated to reach $11.9 million for the province of Ontario (pop. 12M) [9],
or about $1 per capita, per year. As we report below, the yearly cost of major DDI estimated from the
Blumenau EHR dispensation data for the same age group is higher, at least $2 per capita, per year, after
adjusting for inflation and exchange rates—though for less stringent assumptions it can be as high as $7 per
capita, per year. This suggests that the financial burden of DDI is more severe than previously thought.
Moreover, the rate of major DDI found to be dispensed in Blumenau is smaller than what was reported to
be prescribed in Scotland [20]. Therefore the financial burden of DDI is likely higher in other health-care
systems, especially those with older populations.
To characterize the significant factors in DDI, we study demographic variables such as gender and age, as
well as the drugs involved in DDI in greater detail, and reveal previously unknown factors in this phenomenon.
We show that women in Blumenau are at a greater risk of being dispensed known DDI than men, with a 1.6
risk multiplier. This increased risk for females is not confounded by the larger number of women present in
the data nor their age. The analysis also identifies the drug pairs that most lead to DDI in women which,
surprisingly, are not attributable to female-specific medicines (e.g. hormone therapy). We also demonstrate
that there is a significant increase of DDI risk with age, reaching more than 30% for adults over 65 years of
age. Importantly, using a statistical null model, we show that the age risk growth is not explained simply
by the increase in polypharmacy in older age. This suggests that the specific drugs dispensed to older
populations are more prone to DDI and/or that insufficient attention is paid to this phenomenon in primary
care for this population.
While the number of drugs dispensed and the number of concomitant drug dispensations are the best
predictors of DDI (previously only observed for number of drugs prescribed [20]), we show that these quan-
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tities by themselves are poor predictors of DDI. We look at demographic variables such as education and
neighborhood affluence and show they do not play a significant role in the risk for DDI in our data. Other
factors, however, play very significant roles, chiefly age, gender, and the specific drugs dispensed. Indeed,
we demonstrate that the automatic prediction of which patients are dispensed known DDI is quite accurate
when those factors are included. This makes decision-support systems for predicting DDI risk in HIS not
only feasible, but necessary to lower the rates of known DDI being dispensed.
To better understand which drugs are most involved in the DDI phenomenon, we integrate all DDI
information of the Blumenau population into easy-to-visualize DDI networks. Looking at gender differences,
for example, analysis of these networks identifies key drugs and interactions in the DDI phenomenon, and
demonstrates that the higher DDI risk women face is not associated with any type of hormone therapy.
Indeed, drugs that most contribute to the gender-disparity in DDI risk are not female-specific. This suggests
there may be social or biological processes at play in primary- and secondary-care that lead to increased
DDI risk for women. A full listing of the drugs that most contribute to the DDI observed in our study are
presented in our DDI network analysis and accompanying tables.
Results
DDI Demographics, Severity, and Cost
Our analysis tallied Ψ = 1, 025, 754 distinct drug pair co-administrations. Almost 3% of these, or Φ = 26, 524,
are known DDI and involve 75 distinct drugs that participate in |∆| = 181 observed distinct interaction
drug pairs. There is very strong linear relationship between volume of drug dispensation (αN ) and DDI
(ΦN ) across neighborhoods (N) which fits a regression line almost perfectly (R2 = .92, p < 10−6); see
Supplementary Figure 12-right. The distribution of these DDI pairs per severity class is detailed in Table
1. A majority (69%) are labeled Moderate, although, worryingly, 22.5% are classified as Major DDI. The
observed DDI pairs were dispensed to |UΦ| = 15, 527 unique patients, which represent 12% of the Pronto
patient population (and almost 5% of the entire Blumenau population). Looking only at the adult Pronto
population, this number is raised to 15% (15,336). Almost 4% of all Pronto patients (5.01% of adults)
were administered a major DDI, and 9.58% (12.15% of adults) were administered a moderate DDI; these
numbers represent 1.54% and 3.75% of the entire Blumenau population, respectively. See Methods for precise
definitions of symbols and formulae used in this section.
We estimate the financial burden of DDI to Blumenau by evaluating how many of the 24,592 hospital
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severity s Φ |UΦ| |UΦ|/|U | |UΦ|/Ω |UΦ,[y>20]|/|U [y>20]|
Major 5,968 (22.50%) 5,224 3.94% 1.54% 5.01%
Moderate 18,335 (69.13%) 12,711 9.58% 3.75% 12.15%
Minor 542 (2.04%) 528 0.4% 0.16% 0.51%
n/a 1,679 (6.33%) 1,493 1.12% 0.44% 1.43%
Major ∨ Moderate 24,303 (91.63%) 15,030 11.32% 4.44% 14.35%
Moderate ∨ Minor 18,877 (71.17%) 12,791 9.64% 3.77% 12.22%
Table 1: Number and proportions of DDI observations and affected patients per DDI severity class. Drugs
or interactions identified in DrugBank but not present in Drugs.com are tallied as n/a, see SM for details. First column: Φ,
number and proportion of observed DDI co-administrations. Second column: |UΦ|, number of patients affected by at least one
DDI. Third and Fourth columns: proportion of patients from the Pronto system and entire Blumenau populations, respectively.
Fifth column: proportion of adult patients (y ≥ 20 y.o) from the pronto system. ∨ denotes the logical disjunction. Notice that
the same patient may have been administered DDI of more than one severity class.
admissions billed to this public health system in the same period [23] were due to ADR from DDI. This
estimation relies on conjecturing what proportion (ph) of patients who where dispensed a major DDI are
likely to have an ADR that requires hospitalization (details in Supplementary Information §9). We focus
on the most conservative value from available literature [3] which yields ph = 2.68%, as well as on a less
conservative estimate also previously reported [9] of ph = 8.35%. The most conservative estimate leads
to a cost of DDI-related hospitalization in Blumenau of over $1M in the 18-month period, or a per capita
cost of $2.03. The extrapolated costs to the state and the country are $21M and $565M, respectively (see
Supplementary Tables 34 and 35). The less conservative estimate reaches a per capita cost of $6.33, or
$3.2M, $61M, and $1.5B, for the city, state and country levels respectively. However all of these conjectures
are likely to err on the side of under-reporting emergency room admissions due to DDI or ADR, since this is
a well-known problem in studies of this phenomenon [24–27]. Therefore, in Supplementary Information we
also report cost estimates for various values of ph, so that readers can judge what is an appropriate value to
consider.
Drugs Involved in Interactions
Table 2 lists the top 20 DDI pairs, ordered by the rank product of their strength of DDI association, τΦi,j ,
with the number of patients they were administered to, |UΦi,j |. The complete list of DDI pairs, including the
severity class and other measures, is provided in Supplementary Table 7 ordered by the number of affected
patients (see also Supplementary Note 4). τi,j is largest (smallest) for DDI pairs (i, j) that are more (less)
likely to be co-administered when either one of drugs i or j is administered. Computing the rank product
between τΦi,j and |UΦi,j | identifies DDI pairs that are very prevalent in the population but which also tend to
be co-administered.
Only 2% of the observed DDI administrations are considered of minor risk, affecting 542 patients. The
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highest ranked one (9th) in Table 2 is (Digoxin, Spironolactone) and it was administered to |UΦi,j | = 272
patients (for 〈λui,j〉 = 140 days on average); it leads to increased levels of Digoxin while decreasing the effect
of Spironolactone. The vast majority (almost 70% per Table 1) of observed DDI administrations fall in
the moderate risk class. For instance, (Digoxin, Furosemide) can cause “possible electrolyte variations and
arrhythmia” (4th, |UΦi,j | = 385, 〈λui,j〉 = 155). Others, like the pair (Haloperidol, Biperiden; 2nd, |UΦi,j | = 524,
〈λui,j〉 = 243) give rise to various ADR, such as central nervous system depression and tardive dyskinesia;
despite the known ADR this pair has been used clinically [28], which explains the large value of τΦi,j = 0.7,
meaning that these drugs are more likely to be co-administered. In hot weather this DDI increases the risk
of hyperthermia and heat stroke, and Blumenau has a humid subtropical climate with temperatures reaching
30◦C with 100% humidity during summer.
(Omeprazole, Clonazepam) is the most frequent DDI pair observed, by a large margin to the second
(5th, |UΦi,j | = 5, 078, 〈λui,j〉 = 102). Omeprazole is used to treat acid reflux and other gastroesophageal prob-
lems, while Clonazepam is a benzodiazepine anti-epileptic. This prevalent dispensation requires particular
attention to dosage since “Omeprazole may increase the pharmacological effect and serum levels of certain
benzodiazepines via hepatic enzyme inhibition” [28, 29]. Similarly, (Acetylsalicylic Acid (ASA), Glyburide)
is the top ranked pair in Table 2 and very frequently dispensed (1st, |UΦi,j | = 1, 249, 〈λui,j〉 = 141). This
pair is especially problematic for diabetic patients since “the salicylate increases the effect of sulfonylurea;”
It causes hypoglycemia by enhancing insulin sensitivity, particularly in patients with advanced age and/or
renal impairment [28, 30].
rankp(τ, U) τΦi,j |UΦi,j | 〈λui,j〉 i j RRIFi,j class
1 (2,4) 0.60 1249 141 ± 124 ASA Glyburide 0.89 Moderate
2 (1,12) 0.70 524 243 ± 188 Haloperidol Biperiden 0.62 Moderate
3 (4,11) 0.58 535 152 ± 132 Atenolol Glyburide 1.22 Moderate
4 (3,17) 0.60 385 155 ± 125 Digoxin Furosemide 0.61 Moderate
5 (62,1) 0.26 5078 102 ± 95 Omeprazole Clonazepam 2.28 Moderate
6 (8,16) 0.55 470 160 ± 133 Diltiazem Simvastatin 1.27 Major
7 (26,5) 0.45 1190 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
8 (82,2) 0.23 2117 53 ± 74 ASA Ibuprofen 1.42 Major
9 (10,22) 0.55 272 140 ± 114 Digoxin Spironolactone 0.58 Minor
10 (5,46) 0.57 95 140 ± 126 Propranolol Glyburide 1.61 Moderate
11 (15,18) 0.50 377 143 ± 138 Fluoxetine Carbamazepine 0.98 Moderate
12 (91,3) 0.21 1460 54 ± 77 Atenolol Ibuprofen 1.88 Moderate
13 (61,6) 0.27 999 87 ± 86 Omeprazole Diazepam 1.21 Moderate
14 (16,26) 0.49 226 151 ± 145 Amitriptyline Carbamazepine 0.99 Moderate
15 (6,84) 0.56 25 157 ± 136 Diltiazem Amiodarone 1.26 Major
16 (12,47) 0.52 91 154 ± 142 Atenolol Diltiazem 1.19 Major
17 (21,27) 0.47 222 148 ± 139 Fluoxetine Lithium 1.79 Major
18 (40,15) 0.36 496 103 ± 87 ASA Gliclazide 0.78 None
19 (96,7) 0.20 892 56 ± 61 Fluconazole Simvastatin 2.63 Major
19 (14,48) 0.50 90 161 ± 157 Imipramine Carbamazepine 1.35 Moderate
Table 2: Top 20 known DDI pairs. Top 20 known DDI pairs (i, j) by rank product (1st column; individual rank in
parenthesis) of the ranks of τΦi,j , the strength of DDI association from eq. 4, and |UΦi,j |, the number of patients affected by the
DDI (2nd and 3rd columns, respectively). Mean (± s.d.) co-administration length, 〈λui,j〉, is shown in column 4 (in days) for each
DDI pair (i, j) whose English drug names are shown in columns 5 and 6. Relative gender risk of DDI pair co-administration,
RRIFi,j is shown in column 7. DDI severity classification, according to Drugs.com, shown in column 8, with DDIs not found in
Drugs.com labeled as None.
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Major DDI pairs represent 22.5% of all observed DDI administrations per Table 1. The top 20 major
DDI pairs are listed in Supplementary Table 11 and include:
• (Diltiazem, Simvastatin), 6th, |UΦi,j | = 470, 〈λui,j〉 = 160, where “Diltiazem increases the effect and
toxicity of simvastatin” possibly causing liver damage as a side effect [31];
• (Fluoxetine, Amitriptyline), 7th, |UΦi,j | = 1, 190, 〈λui,j〉 = 127, where “Fluoxetine increases the effect
and toxicity of tricyclics” [32]. The same ADR affects (Fluoxetine, Imipramine), 23rd, |UΦi,j | = 257,
and (Fluoxetine, Nortriptyline), 33rd, |UΦi,j | = 154.
• (ASA, Ibuprofen), 8th, |UΦi,j | = 2, 117, 〈λui,j〉 = 53, where “Ibuprofen reduces ASA cardioprotective
effects”. In 2015 the European Medicines Agency issued an updated advice that occasional use of
Ibuprofen should not affect the benefits of low-dose ASA [33]. Our analysis shows that patients were
dispensed this pair concomitantly on average for 53 days (±74 s.d.), conflicting with occasional use.
However, since these are common medications we cannot rule out the possibility they were dispensed
to be taken as needed.
• (Fluoxetine, Lithium), 17th, |UΦi,j | = 222, 〈λui,j〉 = 148), where “the SSRI increases serum levels of
lithium” potentiating the risk of serotonin syndrome, which is rare but serious and potentially fatal
[28, 34];
• (Fluconazole, Simvastatin), 19th, |UΦi,j | = 892, 〈λui,j〉 = 56), which leads to “increased risk of myopa-
thy/rhabdomyolysis”. Also from the azole class, Ketoconazole and Itraconazole are considered potent
inhibitors generally causing less clinically significant interactions with Simvastatin than Fluconazole
[28]. Both substitutes are available free of charge in the public health care system [35].
In addition, the top 20 DDI pairs ranked by a normalized drug “footprint” in the population are listed in
Supplementary Table 12.
Gender Risk and DDI Networks
The set of patients who were co-administered known DDI was comprised of |UΦ,M| = 4, 793 (30.54%) males
and |UΦ,F| = 10, 734 (69.46%) females (see Supplementary Figure 4). To understand whether this difference
in the proportion of DDI per gender was due to Pronto having more female patients (59%), or because women
tend to be prescribed more drugs in general [36], we computed two measures of relative risk of for women.
The relative risk of co-administration for women is RRCF = 1.0653 while their relative risk of interaction
is RRIF = 1.5864. If the risks were equivalent for both genders, we would observe RRCM ≈ RRCF ≈ 1
and RRIM ≈ RRIF ≈ 1. While the relative risk of drug co-administration is only slightly larger (≈ 7%)
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Figure 1: DDI network. A weighted version of network ∆ where weights are defined by τΦi,j . Nodes denote drugs i involved
in at least one co-administration known to be a DDI. Node color represents the highest level of primary action class, as retrieved
from Drugs.com (see legend). Node size represents the probability of interaction PI(i), as defined in text. Edge weights are
the values of τΦi,j obtained from eq. 4. Edge colors denote RRI
g
i,j , where g ∈ {M,F}, to identify DDI edges that are higher
risk for females (blue) or males (red). Color intensity for RRIgi,j varies in [1, 5]; that is, values are clipped at 5.
for females, the relative risk of drug interaction is much larger (≈ 59%). This risk becomes even higher
when we look only at the most dangerous severity class: RRIFmajor = 1.8739, while RRIFminor = .8059 (see
Supplementary Table 22). Removing female anti-contraceptive drugs only slighly lowers RRIF from 1.59 to
1.55.
To understand the DDI phenomenon at large as well as which drugs are most responsible for the higher
risk of DDI women face over men, we also computed DDI networks that characterize drug pairs according to
measures of patient volume (|UΦi,j |) and DDI association strength (τΦi,j). One of these networks is shown in
Figure 1 (others shown in Supplementary Note 6). The 75 drug nodes involved in DDI are colored by their
primary action class. Node size represents the probability of interaction of a drug, PI(i), with larger nodes
identifying drugs most contributing to potential ADR from DDI. To better grasp gender differences in the
DDI phenomenon, edges are colored according to the relative risk of drug pair interaction for each gender,
RRIgi,j with g ∈ {F,M}, such that red (blue) edges denote increased DDI risk for women (men).
8
|UΦ,Fi,j | i j RRIFi,j |UΦ,Mi,j | i j RRIMi,j
13 Carbamazepine Ethinyl Estradiol ∞ 29 Digoxin Amiodarone 1.78
13 Levonorgestrel Carbamazepine ∞ 11 Diclofenac Warfarin 1.19
1,411 ASA Ibuprofen 1.42 -
992 Amitriptyline Fluoxetine 3.55 -
703 Fluconazole Simvastatin 2.63 -
209 Imipramine Fluoxetine 3.08 -
302 Diltiazem Simvastatin 1.27 -
159 Fluoxetine Lithium 1.79 -
122 Fluoxetine Nortriptyline 2.70 -
28 Propranolol Salbutamol 6.61 -
Table 3: Top 10 known major DDI pairs. Top 10 known major DDI pairs (i, j) with increased risk of co-administration
per gender, g ∈ {M,F}, which affected at least 10 patients of each gender. Rows ordered by the rank product of the ranks of
RRIgi,j , the relative gender risk of co-administration, and |UΦ,gi,j |, the number of patients of given gender affected by the DDI.
Of the |∆| = 181 DDI edges, 133 are associated with an increased risk for women, whereas only 48 denote
an increased risk for men—a ratio of 2.8. Removing hormone therapy drugs from the network changes the
number of edges associated with increased risk for women from 133/181 = 73.48% to 116/158 = 73.42%;
for men the ratio changes from 48/181 = 26.52% to 42/158 = 26.58%. In other words, there is virtually no
change when hormone therapy drugs are removed from the network. Looking at the subgraph comprised
only of very gender-imbalanced pairs, RRIgi,j > 3, we find 49 drugs in interactions that affected 3,327 women
(4.28% of female Pronto population), but only 13 drugs in interactions that affected 64 men (0.01% of male
Pronto population). The 65 (9) such interactions for women (men) contain 16 (3) that are considered major
(see also Supplementary Figure 8). Table 3 shows the top major DDI pairs per gender which affected at least
10 patients; interestingly, only two DDI pairs that affect at least 10 patients were observed with a higher
relative risk of interaction for males—see Supplementary Tables 18 and 19 for full listings.
Age Risk
To investigate the role of age in DDI co-administration we calculated two additional measures, the risk
of co-administration for age group, RC [y1,y2], and the risk of interaction for age group, RI [y1,y2]. If the
number of DDI observed were proportional to the number of co-administrations, the latter quantity would
be essentially flat across age groups (see eq. 8 in Methods). As shown in Figure 2, center, RI increases
substantially for older age groups (see also Supplementary Table 23), varying from near zero for younger age
groups to 0.35 for groups over 70. While there is some variation, RC varies a lot less than RI—no more
than 6% across all age groups as seen Figure 2-left (note the difference in scale). This shows that risk of
co-administration is largely proportional to the number of dispensed drugs, while risk of interaction seems
to grow more than the increase in co-administrations (polypharmacy) observed with age.
The risk of co-administration is overall quite high for all age groups (RC [y1,y2] ∈ [.92, .98]), with increasing
values as patients age. Patients dispensed at least two drugs are almost always being dispensed drugs
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Figure 2: Risk of co-administration and interaction per age range. A & B. Co-administration (RC[y1,y2]) and
interaction risk (RI[y1,y2]) per age group, computed via eq. 8. Solid orange line is the cubic regression for RC[y1,y2] while
solid red line is the cubic regression for RI[y1,y2] (linear and quadratic regressions in Supplementary Information). C. Absolute
number of patients with at least one co-administration known to be a DDI. For all plots, age groups [90,94], [95,99) were
aggregated into [90+]. Stars (?) depict values computed from the null model, Hrnd0 , with background filling denoting the 95%
confidence interval based on 100 runs.
concomitantly. Conversely, the risk of interaction starts from almost nonexistent at age [0-14] and reaches
more than 25% after the age of 55.
The relationship among the number of drugs dispensed (νu), co-administrations (Ψu), and interactions
(Φu) for all users is shown in Figure 3. While there is a strong nonlinear (quadratic) relationship between
νu and Ψu (Fig. 3-D), there is no evidence of a nonlinear relationship between Ψu and Φu (Fig. 3-F), which
could explain the observed growth of RI with age—which implies that interactions grow faster than co-
administrations with age. In contrast to previous reports [20], co-administrations (Ψu) predict interactions
(Φu) better than number of drugs prescribed (νu), though neither do so particularly well.
To further investigate whether factors other than increase in co-administration cause the increase of DDI
risk with age, we developed a statistical null model; values reported for the null model are identified with
a star (?) and associated 95% confidence intervals (for 100 runs) in Figure 2. The idea is to explore if the
growth of RIy is an expected phenomenon of increased polypharmacy with age, which necessarily results in
a combinatorial increase of possible drug pairs that can interact. The null model was not able to reproduce
the observed behavior of RIy (X2 = 2840.6, p < .01), especially for older and younger ages (see Figures 2
and 4 and Supplementary Information §7 for additional details).
We observe that for younger ages, RI [0,29] is much lower than the model’s predicted RI [0,29]? (Fig. 2-b);
the same is true for the number of patients affected (Fig. 2-c). The largest discrepancies between model and
real data occur at this age range, especially [0,4] and [20,24]. However, this expected behavior is inverted
for ages [50+], with the transition occurring around age [40,44] (Fig. 2-b). For older ages, the largest
discrepancies between model and reality occur for age groups in [50,70], where the predicted number of
patients with DDI (|UΦ?|) for age group [60,64] is 16% lower than what is observed (see Fig. 2-c).
We additionally parse age risk by gender by computing RC [y1,y2],g and RI [y1,y2],g, shown in Figure 4
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with stronger red (blue) representing older women (men). To reduce circle overlay and enhance visualization, a uniform noise
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Figure 4: Risk of co-administration and interaction per age range and gender. A. Risk of co-administration per age
group and gender, RC[y1,y2],g . B Risk of interaction per age group and gender, RI[y1,y2],g . C. Absolute number of patients
with at least one known DDI co-administration, per age and gender UΦ,[y1,y2],g . D & E. Female and male risk of interaction per
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into [90+]. Stars (?) depict values computed from the null model, Hrnd0 , with background filling denoting the 95% confidence
interval based on 100 runs. Shaded areas identify specific age groups mentioned in the main manuscript.
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(see also Supplementary Tables 24 and 25). Both genders have overall similar risk of co-administration in
all age groups. Even during childbearing age, the co-administration risk is similar for the numbers of drugs
dispensed, even if slightly larger for females (see filling in Fig. 4-top-left). Interestingly, for RI [y1,y2],g a clear
difference between genders occurs after childbearing age, maximized between 50 and 69 years-old (see filling
in Fig. 4-top-right and absolute number of patients in Fig. 4-middle). The gender difference in RI appears
after the age of 35, reaching more than a 9% difference for age group [60,64].
Figure 4 d-e show the null model’s gender risk of interaction RI [y1,y2],g?, in comparison to observed
values, RI [y1,y2],g, for men (d) and women (e), respectively. For both genders, we still observe that the real
RI for children and young adults ([0,34]) is well below the null model. However, the transition observed for
older age is much more pronounced for women. In fact, after age 40, observed male RI is largely consistent
with the null model, while female risk is higher.
Prediction of Patients with DDI
We computed several multiple regression (MR) models. These show that the inclusion of additional variables
does not improve much at all the prediction of the variance of Φu. For instance, a MR with both νu and Ψu
leads only to very marginal increase in the explained variance of Φu: adjusted R2 = 0.492. Adding higher
order, nonlinear models also does not improve upon the original regression between Ψu and Φu. Even the
inclusion of demographic variables in MR models does not lead to improvement of R2 for Φu—we analyzed
many neighborhood-level variables such as average income, robbery, theft, suicide, transit crime, trafficking
and rape rates. Restricting the analysis to the subset of patients who reported education, and using it as an
independent categorical variable also yields no improvement (see Supplementary Information §10.2 for MR
and ANOVA details).
Interestingly, even the inclusion of gender as a categorical variable, does not improve R2 for Φu. At first
glance, this seems a somewhat counter intuitive result, given the observed high risk of DDI for females in
comparison to males. However, the MR analysis revealed that even though women certainly face a much
greater risk of DDI, the number of DDI pairs they are administered (Φu) is on average similar to that of
men, and both have large variance of Φu (see Supplementary Figure 5). Thus, while gender clearly is a very
strong factor in the risk of at least one DDI, it is not a good predictor of the specific number of interactions
per patient.
Therefore, we sought to answer the question of how well we can automatically predict patients with at
least one DDI (not the number of interactions per patient)? Using binary classifiers we are able to achieve
very good performance on this task. Classifiers perform well above null models, with MCC ≈ 0.7 and
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excellent AUC scores: AUC ROC ≈ 0.97 and AUC P/R ≈ 0.83.
Discussion
Our 18-month longitudinal analysis of EHR data of the entire city of Blumenau allowed us to study the
DDI problem in primary and secondary care in greater detail and for a longer period of time than what
has been hitherto possible. In summary, the DDI phenomenon is stable across the city, and proportional to
population size—demonstrating no major inequalities due to income, education, crime, or other neighborhood
social factors, which suggests a balanced and fair access to medical care in Blumenau. Our analysis revealed
that ≈ 12% of all patients of the Pronto HIS where administered known DDI, which represents 5% of the
entire Blumenau population. If we consider only the adult population, ≈ 15% were dispensed a known DDI
(more than 6% of the Blumenau adult population). Looking at the type of DDI, we observe that 4% of all
patients (5% of adults) were dispensed a major DDI likely to result in a very serious ADR—almost 2% of
the city’s population.
Given the lack of similar studies, we cannot directly compare the rate of DDI severity observed in
Blumenau to other public health systems. The Tayside study (with a smaller, 84 day observation window)
reported a rate of 13% “potentially serious” DDI for adult patients [20]. This severity class was derived
from the British National Formulary, a private publication we do not have access to. If this severity is
similar to the Drugs.com major DDI class, then Blumenau has a considerably lower rate of this type of
DDI than Tayside—5% to 13%. If, on the other hand, “potentially serious” encompasses both the major
and moderate Drugs.com DDI classes, then the rates observed in Blumenau are similar to those observed in
Tayside—14.35% to 13%.
We uncovered 181 DDI pairs that most likely could have been prevented [12]. These drugs known to
interact were nonetheless dispensed for co-administration to 15,527 people, including more than five thousand
who were administered a major DDI, likely to require medical attention. In addition to the human suffering
caused, patient hospitalization due to major DDI may lead to a large financial burden to health-care systems.
All our estimates lead to very substantial costs for the various levels of government, suggesting that the
financial burden of DDI is at least double what was previously reported—$1 per capita in Ontario [9]—
even when considering the most conservative estimate of the proportion of hospitalizations that derive from
co-administration of known major DDIs. Thus, our large-scale longitudinal analysis suggests that previous
estimates based on smaller studies likely underestimate the cost of the DDI phenomenon.
We provide comprehensive lists of the DDI pairs uncovered in the data, allowing others to look at specific
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drugs of interest. The data can be seen from different angles, such as the volume of people affected or the
likelihood that certain drugs are co-administered. These include common medications such as proton-pump
inhibitors (Omeprazole), anti-depressants (Fluoxetine), or common analgesics (Ibuprofen), as well as not
so common drugs (e.g. Erythromycin). It is noteworthy that the DDI co-administration of CYP(3A4 and
2D6) inhibitors with their respective enzymes substrates was often found in our results. From our dataset
CYP[3A4] inhibitors include Omeprazole, Fluconazole and Erythromycin and their respective substrates
include Clonazepam, Simvastatin and Carbamazepine. Recently, the FDA included a comparison list [37] of
in vitro and clinical inhibitors, inducers and substrates for CYP-mediated metabolisms. In agreement with
previous work [16], our analysis revealed several such DDI, including the most common DDI pair in our data
(Omeprazole, Clonazepam). Many other major interactions, while not ranked at the top, are nonetheless
of concern due to severe ADR. For instance, in 2011 the FDA issued a warning [38] contraindicating the
concomitant use of Simvastatin with Erythromycin, due to increased risk of myopathy by “possibly increasing
the statin toxicity”. Still, our analysis identified 10 patients concomitantly administrating this major DDI
(117th, |UΦi,j | = 10), also known for its increased risk of liver damage and a rare but serious condition of
rhabdomyolysis that involves the breakdown of skeletal muscle tissue [28, 39].
Our network representation also allows us to integrate, summarize and visualize the DDI phenomenon.
The analysis of the network itself also reveals nodes with largest degree, that is, drugs that participate
in more known DDI. The top ones, participating in over 10 distinct DDI are: Phenytoin, Carbamazepine,
Phenobarbital, Propranolol, Warfarin, Aminophylline, Fluoxetine, Fluconazole (see Supplementary Table
27 for others). Drugs in italic have both high degree and high PI, meaning they interact with many other
drugs and are also more likely to interact with some other drug when dispensed. The network also allows
us to investigate the roles of individual drugs and DDI pairs, in relation to others. For instance, Phenytoin,
an anti-seizure medication, is the drug with largest degree and node size: it interacts with 24 other drugs,
granting it the highest total degree strength,
∑
j τ
Φ
ij = 6.51; 1 in 5 times that Phenytoin is co-administered
with another drug it leads to an interaction, PI(Phenytoin) = 0.2; and it also has the largest betweeness
centrality (0.30) [40], thus acting as bridge between other drugs with known DDI.
Our characterization of the significant demographic factors in the DDI phenomenon, shows that women in
Blumenau are at a strikingly greater risk of being dispensed known DDI than men, with a 1.6 risk multiplier.
In other words, women in the Blumenau’s Pronto system have an almost 60% increased risk over men of
being dispensed a DDI, but only a 6.5% increased risk of being dispensed drugs concomitantly. When only
major DDI are considered the risk multiplier is even higher: 1.9. That is, women have almost double the
risk of men of being dispensed a major known DDI. It is noteworthy that we pursued a relative risk analysis
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for all age groups, showing that females face a greater or similar risk of DDI than males in all age groups,
with substantially higher risk observed after 50 years of age. For instance, in age group [60-64], 1 in 3 women
who are dispensed two or more drugs concomitantly face a known DDI, whereas that ratio is less than 1 in
4 for men for the same age group (see Figure 4). Therefore increased risk for females is not confounded by
the larger number of women present in the data nor their age.
It is known that age is also a factor in predicting the number of prescribed drugs [36], especially because
of increased co-morbidity in older patients. Our analysis shows that one in every four patients over 55 is
likely to be face a known DDI when co-dispensed two or more drugs. The risk of interaction for older age
groups of both genders is also severe, reaching more than 30% for adults over 70 years of age in comparison
to younger age groups. While a greater risk for older age groups is expected due to increased polypharmacy
with age, a comparison of the observed risk with a null model accounting for random polypharmacy (and
preserving same number of co-administrations per age) shows that it does not explain the high levels of
interactions older age groups face. This can be contrasted with the almost nonexistent number and risk of
interactions in children, which are considerably lower than what the null model predicts for polypharmacy
at that age. It is very surprising, indeed shocking, that there are more cases (and increased risk) of DDI in
older age than random (age-conditioned) dispensation of drugs would yield. We would expect all age groups
to have fewer cases than a random null model, but this is only observed for younger age groups.
The null model also revealed an additional gender bias, as older women clearly have a worse-than-random,
while older men have a more similar-to-random risk of DDI in most age groups. In fact, deviation from the
null model in older age is mostly explained by increased risk for females. In contrast, younger age groups of
both genders have much better-than-random risk of DDI.
These observed gender and age risks suggest two possible hypothesis: specific drugs dispensed to women
or older populations are more dangerous; and/or that not as much attention to DDI in primary care is
reserved for these populations. The fact that the specific drugs dispensed greatly improve the automatic
prediction of patients with DDI favors the first hypothesis, but given the age and gender risks observed, it
is also clear that the same DDI-prone drugs are administered differently between genders and across age
groups. This second hypothesis is strengthened by the fact that removing female-specific hormone therapy
from the the DDI network of Figure 1 barely reduces the DDI gender risk (from 59 to 55%). Indeed, the
DDI pairs with increased risk for women traverse all drug classes and are not gender-specific, ranging from
cardiovascular to central nervous systems agents.
While it was already known that drugs withdrawn from the market for ADR presented greater risks for
women [41], our study demonstrates that women (and older populations) in Blumenau also face a higher risk
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of being dispensed known DDI. It could be that in older age groups (especially for women) there are fewer
alternative drugs (with fewer adverse reactions) in the Blumenau public system, either because they are more
expensive or simply because they are not available anywhere, thus forcing the prescription of known DDI.
These and other possibilities warrant further study outside the scope of the present article. For instance,
would the introduction of newer and costlier drugs into the public system, overcome the financial and human
burden of current DDI levels? Nonetheless, since medical care should in principle provide a better-than-
random risk of DDI for all age groups and genders, our results suggest that factors of a social, biological,
or medical-care nature are at play at the primary- and secondary-care levels and should be further studied
everywhere.
The performance achieved by our classifiers demonstrates that a useful computational intelligence pipeline
can be devised to flag patients for further assessment by a primary care physician, pharmacist, public official,
or even to request a home visit from a community health agent. Existing prescription alert systems already
warn against known DDI, still, these are evidently being prescribed in worrying numbers. This could be
because there are good medical reasons to prescribe certain drug combinations despite known DDI risk,
or because drugs may be prescribed by distinct physicians, who may not be aware of or check previous
prescriptions, or simply dismiss HIS alerts [42]—perhaps due to physician alert fatigue [43].
To be useful, personalized alert systems based on the type of predictions produced by our classifiers do
not necessarily need to be added to prescription systems. Indeed, their utility lies not in identifying known
DDI pairs—as those are already by definition available via formularies, web resources like Drugbank, or
prescription HIS—but rather in identifying patients at greater risk of being prescribed DDI in the future, or
subpopulations and comorbidities that for social or biomedical reasons face greater risk of DDI. Thus, they
should be more useful for those involved in integrating and managing the care of individual patients or the
entire public-health system. Those are decisions that each public-health system will have to weight. Still,
our work demonstrates that a personalized alert system for DDI is accurate and can be used to reduce the
DDI phenomenon not only in future versions of the Pronto HIS, but in other cities that have observed high
levels of DDI—e.g. the Tayside region, in Scotland [20]. In future work we intend to add such a pipeline to
Pronto as well as utilize new data sources such as social media, since Pronto already includes such patient
handles. Indeed, such data may allow early-warning signal detection of adverse events and DDI [44, 45].
Large-scale analyses of EHR to establish the prevalence of known DDI are rare. Most studies are obtained
from small populations in hospital settings, so they vary by a large margin [6, 11, 12, 46]. Our study of
the entire city of Blumenau at the primary- and secondary-care level offers an important new large-scale
measurement of the DDI phenomenon in a public health-care system—a baseline that can be compared
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to other worldwide locations beyond Brazil, as EHR data becomes available. For instance, are the gender
and age risk levels we observed similar in other primary- and secondary-care settings? Are there cultural or
public/private differences? Will the health systems of other cities also prove to be unaffected by neighborhood
and income levels, etc?
Our large-scale epidemiological analysis demonstrates that an integrated data- and network-science ap-
proach to public health can uncover biases in the DDI phenomenon as well as yield tools capable of issuing
accurate DDI prediction per patient. Both outcomes contribute to preventing ADR from DDI and thus may
lead to a significant positive impact on the quality of life of patients and finances of public-health systems.
Moreover, the gender and age risks of DDI we discovered, should inform physicians and other health profes-
sionals anywhere that such factors are important in the drug management of their patients. We expect the
results to increase awareness of those risks we uncovered.
Methods
Data
Eighteen months of drug dispensing data (Jan 2014-Jun 2015) were gathered from the Pronto HIS [47, 48]
(see Supplemental Note 1 for a system description). Drugs reported in this system are available via medical
prescription only, free of charge, and dispensed to citizens of Blumenau (population Ω = 338, 876 [49]) during
the observation period. Doctors prescribe medications by selecting drug and dosage via the HIS. Low-cost
drugs can generally be directly dispensed at the primary-care facilities, whereas specialized and higher-cost
medication is distributed in three central facilities across the city. All drugs are dispensed by pharmacists
who must select in Pronto the drug and quantity to be dispensed, allowing the length of administration to
be estimated. It must be noted that patients are not required to retrieve drugs from the public system. They
can buy prescribed medications from private pharmacies at their own expense, without such transactions
being recorded in Pronto. However, there is no incentive to pay more at private pharmacies for the same
medication. Indeed, our analysis indicates that use of Pronto is similar across all neighborhoods of Blumenau,
irrespective of their average income (see Supplementary Figure 3).
EHR were anonymized at the source and only drug dispensation and demographic variables, including
gender, age, neighborhood, marital status and educational level, were kept. Methods were performed in
accordance with guidelines and regulations. All patient consent was handled at the source prior to the
anonymization and outside of the responsibility of this team. Nonetheless, this study was approved by Indi-
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Figure 5: Distribution of patients given gender, age and education level. In total |UM| = 55, 032 (41.46%) were
males and |UF| = 77, 690 (58.54%) were females. On education, a majority |Ue=∅| = 71, 662 (53.99%) did not report their
education level. |Ue−| = 48, 547 (36,58%) declared having at most some high school education whereas |Ue+| = 12, 513 (9,43%)
had completed high school education or above. On age, patients |Uy=[20,24]| = 10, 382 (7,82%) and |Uy=[50,54]| = 10, 650
(8,02%) accounted for the two largest age groups. Labels K-6 and K-12 are Completed elementary and Completed high school
education, respectively. Labels for age y ≥ 80 and education level above Completed college not shown.
ana University’s Institutional Review Board (IRB). Drug names originally in Portuguese were converted to
English, disambiguated and matched to their DrugBank ID (e.g., Cefalexina 500mg Comprimido and Ce-
falexina 250MG/5ml Suspensão Oral were matched to Chlorphenamine, DBID DB01114). Medications with
multiple drug compounds (e.g., Amoxicillin 500mg & Clavulanate 125mg) were split into their constituent
individual drugs. Other dispensed substances (e.g., infant formula milk or vitamin complexes) unmatched
to DrugBank were discarded. In total, 122 unique drugs were keep for analysis. Because we have no means
to know whether patients actually took the dispensed drugs, our analysis assumes that drugs dispensed were
administered.
Throughout the year of 2014 and the first six months of 2015, Blumenau’s Pronto HIS registered 1, 573, 678
distinct drug interval administrations, dispensed to |U | = 132, 722 distinct patients—39.17% of the city
population. The male/female proportions are 41.5/58.5%, respectively. Of the 46% who declared their
education level, a large proportion (46.77%) reported having incomplete elementary school and 20.49%
had finished high school or above (see Supplementary Figure 5 for details). |Uν≥2| = 104, 811 patients,
corresponding to 78.97% of the Pronto patient population, were dispensed two or more distinct drugs in the
period; only this set could have been dispensed known DDI.
Methods
A drug interaction between a pair of drugs is measured if both drugs were concomitantly administered and the
pair is identified as a known DDI in the 2011 version of DrugBank, an open-source drug database containing
DDI information [50]. Figure 6 displays a co-administration timeline example. More formally (see also Table
4 and Supplemental Note 3), let us denote patients by u ∈ U and drugs by i, j ∈ D (|D| = 122); Ui ∈ U
is the subset of users who were dispensed drug i, Du ⊆ D is the subset of drugs administered to patient u,
and νu ≡ |Du| is the number of distinct drugs dispensed to patient u. Patients can be administered a drug
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Figure 6: Diagram of co-administration and interaction computation. A. A hypothetical patient-drug dispensing
timeline with three drugs (i,j & k). Drug administration length (a, in days, n) are shown for each dispensation. B. The three
possible pairwise comparisons (i, j), (i, k) and (j, k) between the dispensed drugs are shown with their co-administration overlap
marked with either an orange (no known DDI) or red (known DDI) background.
i multiple times in the observation period, therefore Aui ≡ {ai,un } denotes the set of distinct administration
intervals a of drug i to patient u, where a ∈ N is measured in days (n). αui = |Aui | and λui =
∑
n a
i,u
n denote
the number of times and total number of days drug i was administered to patient u, respectively.
Similarly, αui,j and λui,j denote the number of times and total number of days (co-administration length)
drugs i and j were co-administered to patient u, respectively (see Supplementary Information §2 for more
details of co-administration measurement). To identify the co-administration of drug pair (i, j) to patient u
we define a Boolean variable ψui,j ∈ {0, 1} as:
ψui,j =
(
λui,j > 0
)
(1)
a logical variable measuring whether patient u co-administered drug pair (i, j) for at least one day. Next,
we define a symmetrical binary map ∆ : D × D → {0, 1} to indicate whether drug pair (i, j) ∈ D × D is
(δi,j = 1) a known DDI in DrugBank, or not (δi,j = 0). Thus, to flag the co-administration of a known drug
interaction (i, j) to patient u we similarly define a Boolean variable ϕui,j ∈ {0, 1} as:
ϕui,j =
(
ψui,j = 1 ∧ δi,j = 1
)
. (2)
For each DDI pair observed, literature references and a severity score s ∈ {major,moderate,minor, n/a}
were retrieved from Drugs.com [28]. From these values, other quantities and sets are computed per patient
u, drug i or drug pair (i, j) as listed in Table 4.
The drug pairs (i, j) with the largest “footprint” in the population, are the pairs that maximize |UΨi,j |.
Out of these most co-administered pairs, we are naturally most interested in those that are known DDI and
20
quantity notation number of
νu ≡ |Du| distinct drugs dispensed to patient u.
Ψu =
∑
i,j∈Du
ψui,j co-administrations to patient u.
Ψi,j =
∑
u∈U
ψui,j co-administrations of drug pair (i, j) to all patients.
Φu =
∑
i,j∈Du
ϕui,j co-administrations of known DDI pairs to patient u.
Φi,j =
∑
u∈U
ϕui,j co-administrations of known DDI pair (i, j) to all pa-
tients.
subset notation subset of patients
Uν>x = {u ∈ U : νu > x} who had at least x ∈ N drug administrations.
UΨ = {u ∈ U : Ψu > 0} who had at least 1 co-administration.
UΨi,j = {u ∈ U : ψui,j = 1} who co-administered drug pair (i, j).
UΦ = {u ∈ U : Φu > 0} who had at least 1 known DDI.
UΦi,j = {u ∈ U : ϕui,j = 1} who co-administered known DDI pair (i, j).
Ug = {u ∈ U : gender(u) = g}, g ∈ {M,F} per gender.
U [y1,y2] = {u ∈ U : age(u) ∈ [y1, y2]}, y1, y2 ∈ N per age bracket.
UN = {u ∈ U : neighborhood(u) ∈ N}, N ∈ N per neighborhood.
UE = {u ∈ U : education(u) ≥ E}, E ∈ N per education level. UE=∅ is the subset of pa-
tients who did not report their education level.
From these subsets we also denote their possible intersections by combining the appropriate sub and superscripts.
Table 4: Co-administration and interaction quantities and subsets used throughout the analysis.
thus maximize |UΦi,j |. A normalized version of this measure is computed as
γΦi,j =
|UΦi,j |
|Ui| , (3)
which conditions the number of users co-administered known DDI pair (i, j) on the number of users that are
administered drug i. This measure is not symmetrical: γΦi,j 6= γΦj,i. Maximizing it yields DDI pairs (i, j) that
tend to be co-administered to patients who are administered either i or j independently; see Supplementary
Table 12 for top 20 such DDI pairs.
Another facet of the DDI phenomenon we can observe is related to the co-administration length of drug
pairs (λui,j). A normalized version is computed as: τui,j = λui,j/(λui + λuj − λui,j), where τ ∈ [0, 1]. This
symmetric proximity measure [51] allows us to distinguish drug pairs that tend to be co-administered to
patient u only simultaneously (τui,j → 1), or with small temporal overlap (τui,j → 0). A normalized measure
for the entire patient population is then computed as:
τΨi,j =
∑
u∈UΨi,j
τui,j
|UΨi,j |
(4)
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This proximity measure defines a weighted graph TΨ [51] on set D; the graph’s edges, τΨi,j ∈ [0, 1], link
drugs that were co-administered in the patient population. τΨi,j is larger when drug pairs (i, j) tend to be co-
administered when either i or j is administered (correlated), and smaller otherwise (independent). Therefore,
τΨi,j is a measure of the strength of drug association in the data for drug pairs (i, j); high values can pick
drug pairs dispensed together for known comorbidities, which physicians should be aware of, as well as for
unknown cormobidities (especially involving distinct specialists prescribing drugs independently). Since we
do not know the underlying comorbidities, we cannot separate the two cases with this dataset. However, to
focus on the DDI phenomenon (for known and unknown comorbidity), we obtain a subgraph TΦ, restricted
to known DDI pairs by computing τΦi,j = τΨi,j .δi,j ; thus, TΦ is a weighted version of ∆.
Gender Risk
The relative risk of co-administration (RRC) for women is computed as the ratio of the conditional proba-
bilities of patients being dispensed at least one pair of drugs concomitantly, given gender:
RRCF =
P (Ψu > 0 |u ∈ UF)
P (Ψu > 0 |u ∈ UM) =
|UΨ,F | /|UF|
|UΨ,M | /|UM| (5)
Naturally, the same risk for males is computed as RRCM = 1/RRCF. Similarly, we also computed the
relative risk of interaction (RRI) for women as:
RRIF =
P (Φu > 0 |u ∈ UF)
P (Φu > 0 |u ∈ UM) =
|UΦ,F | /|UF|
|UΦ,M | /|UM| (6)
with RRIM = 1/RRIF.
DDI Network
The DDI Network is a weighted version of graph ∆ where edge weights between drugs i, j (nodes in graph)
are the values τΦi,j obtained from eq. 4—yielding a proximity between drug pairs according to their co-
occurrence in DDI co-administrations when either drug is administered (a symmetrical measure of strength
of association/correlation [51]). Node size represents the probability of interaction for drug i:
PI(i) =
∑
j Φi,j∑
j Ψi,j
(7)
which denotes the propensity of drug i to be involved in a DDI with all drugs it is co-administered with in
the data (see Supplementary Table 27 for values); larger nodes thus identify more dangerous drugs in the
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sense that they most contribute to potential ADR from DDI in our data.
To better grasp gender differences in the DDI phenomenon, edges are colored according to the relative
risk of drug pair interaction for each gender : RRIgi,j where g ∈ {M,F}. These quantities are computed
for each DDI pair (i, j) via eq. 6, but using Φui,j (number of co-administrations of known DDI pair (i, j)
to patient u) instead of Φu. Naturally, RRIFi,j = 1/RRIMi,j . If RRIFi,j > 1, the edge is colored in red
with intensity proportional to RRIFi,j , otherwise the edge is colored in blue with intensity proportional to
RRIMi,j (see legend). Therefore, increased DDI risk for women (men) is identified by darker red (blue) edges.
Supplementary Tables 18 and 19 show the RRIgi,j values for the top most gender imbalanced DDI pairs per
gender.
For some results we remove the following contraceptive drugs: Ethinyl Estradiol, Estradiol, Norethis-
terone, Levonorgestrel and Estrogens Conjugated.
Age Risk
To investigate the role of age in known DDI co-administration, we aggregated patients into age groups and
computed the risk of specific age groups to be dispensed a known DDI for the amount of co-administrations
observed for that age group. Thus, a risk of interaction for age group [y1, y2] is calculated as
RI [y1,y2] =
P (Φu > 0 |u ∈ U [y1,y2])
P (Ψu > 0 |u ∈ U [y1,y2]) , (8)
which can be interpreted as the probability of being dispensed a known DDI given the expected number of
co-administrations for a patient in a specific age range [y1, y2]. A Risk of Co-administration for age group
[y1, y2], RC [y1,y2], is similarly computed, but using νu ≥ 2—the number of patients with at least 2 drug
administrations—instead of Ψu. This is interpreted as the probability of being concomitantly dispensed two
or more drugs (co-administration), when a patient of a given age group is dispensed two or more drugs in
the full observation period. Additionally, we also parse age risk by gender by computing RI [y1,y2],g for each
gender g ∈ {M,F} using eq. 8, but for users u ∈ U [y1,y2],g. Similarly, RC [y1,y2],g is computed for the risk of
co-administration per age and gender.
Null Model
The null model, Hrnd0 , aims to capture the expected increase in RIy with age, given the observed polyphar-
macy and gender for each specific age group. Thus, the model’s assumption is that all drugs that were
in reality dispensed in a given age group are dispensed at random with the same overall frequency of co-
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administration for that age group. Specifically, for each co-administration observed in the data for an age
group [y1, y2], the null model draws random drug pairs (i, j) from the set of all drugs observed for that age
group, D[y1,y2]. The random drug pairs are subsequently checked for DDI status in DrugBank, just like the
original analysis. This way, the null model has exactly the same number of co-administration occurrences
for each age group and gender, but randomly shuffled drug pairs—and only the drugs dispensed for a certain
age are randomly shuffled for that age group (additional details in Supplementary Note 7).
Machine Learning Classifiers
We trained linear kernel Support Vector Machine (SVM) [52] and Logistic Regression (LR) [53] classifiers
using stratified 4-fold cross-validation to ensure generalization performance (additional details in Supplemen-
tary Note 11). Age, gender, number of drugs (νu) and co-administrations (Φu) were used as demographic
variables features. In addition, all |D| = 122 drugs in the data are used as binary features, whereby if patient
u was administered drug i that feature is set to 1 and to 0 otherwise; this allows classifiers to be trained on
which drugs, and drug combinations, are most likely to be involved in DDI.
The trained classifiers are compared to two “coin-toss” null models, one unbiased where each class has
equal probability, and a biased one based on estimated class frequency. A third, more elaborate null model
classifier, finds the best age cutoff for each gender, from which all patients above the cutoff age are considered
as having a DDI. This last “age-gender” null model represents a baseline comparison of the best we could do if
only gender and age were given for each patient. To assess the performance of all classifiers, in Supplementary
Note 11 we report several measures. Here, we focus on the Matthew’s Correlation Coefficient (MCC) [54],
which is regarded as an ideal measure of the quality of binary classification in unbalanced scenarios such
as this [55]. We also report two other measures widely used in machine learning classifier performance, the
area under the receiver operating charactistic curve (AUC ROC), and the area under the precision and recall
curve (AUC P/R).
Other classifiers, feature selection and cross-validation techniques can be used to increase performance,
but such gains when studying the DDI phenomenon do not typically lead to substantial performance increases
[56], so such optimization is beyond the scope of this article.
Code Availability Statement
Custom python and R scripts are available in github.com/rionbr/DDIBlumenau.
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Data Availability Statement
The anonymized data that support the findings of this study are available from the city of Blumenau, Brazil.
Restrictions apply to the availability of these data, as they may contain information that could compromise
research participant privacy through de-anonymization. The data were used under a license agreement, and
so are not publicly available, but are however available from the authors upon reasonable request and with
permission of the city of Blumenau. All data tables and aggregates are available in appropriate electronic
form.
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Supplementary Note 1 Pronto: academia, government and
patients
This section explores some important details about the health information system that made the data
presented in this paper possible and tries to enlighten for the broader impact of such projects.
1.1 The need for a city-wide HIS
Apart from systems nationally developed for specific health attention policies—vital statistics, mortality,
epidemiology, diabetes, etc—Brazil has no universal electronic health record (EHR) country-wide [1, 2]. Only
secondary care (specialists) or high-cost procedures are fed into federal HIS that contains user identification
with their national health card (Cartão Nacional de Saúde; CNS), even though the majority of services
are performed at primary care [1]. The CNS, initiated in 1999 [3], was the initial step towards a unified
EHR, but several difficulties were met along these now 20 years of the program [4–6]. Thus, it is currently
not possible to follow patients across systems—specially those that only access primary care—or request to
the system their medical record. At the city level, most big cities have enough funds to buy specialized,
private HIS, to develop and implement EHR along with an intra-city public health development plan for its
citizens. On the other hand, the vast majority of small and mid-cities (there are 5,336 cities with less than
100.000 inhabitants [7]) hardly have financial access to the same costly solutions, and most of the information
still transits on paper. Still, the necessity to manage several primary care installations, hundreds of health
professional agendas and input city-level information into federal HIS takes place.
To address this need in the city of Blumenau, southern Brazil, the municipal government and the regional
university (Universidade Regional de Blumenau; FURB) joined forces to develop their own open-source
HIS to collect and store EHR for its citizens. The system, named Pronto, was built by the Laboratory
of Technology Development and Transfer (Laboratório de Desenvolvimento e Transferência de Tecnologia;
LDTT [8]), a small transdisciplinary [9] team of professors and students from diverse fields of research—such
as compute science, nursing, medicine, dentistry, psychology, communication, and others—at FURB. This
enterprise, bridging academia, government and private sector [10], spun off several scientific quests [8, 11–13]
in order to enhance the quality of life of patients in Blumenau, broadening FURB’s societal impact, and
enabling patients to experience outcomes of scientific research first hand.
After development and deployment, the technology was transferred to the private sector under public
bidding regulations, and continues to this day to serve as Blumenau’s public health care system under
municipal oversight. Pronto is currently used in all health institutions throughout the city. From primary
to specialized care—hospitals have their own specialized system—and drug dispensing units. The system
currently maintains health professional agendas, integrated medical and dental records, and drug prescription
and dispensing across more than 30 health care units.
Doctors prescribe medications by selecting drug and dosage in the electronic system. Low-cost drugs can
generally be directly dispensed at the primary-care facilities, whereas specialized and higher-cost medication
are distributed in three central facilities across the city. All drugs are dispensed by pharmacists who must
select in Pronto the drug and quantity to be dispensed, allowing the length of administration to be estimated.
There is no pill manipulation as all drugs are dispensed in their original sealed packaging. The database also
stores inventory information—in case of drug recall, for instance, patients can be contacted in regards to a
specific drug lot.
Pronto runs on a custom built, decentralized database model, where each individual health unit has its
own database and a master-to-master replication takes place asynchronously, a design feature due to the
unreliable network infrastructure in rural areas. Included in the technical challenges faced by the developing
team were also the heterogeneous data feed from multiple health professionals; the transformation from such
data data into insightful knowledge to diverse stakeholders, and the constant adaptation to match city as
well as state and federal regulations.
A city-wide unified EHR enables a variety of scientific research questions, but most importantly, it permits
a holistic approach to public health care. Since patients may enter the system at different clinics throughout
the city, the system enables their EHR to be present whenever they go. Moreover, since different health
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professionals have access to the EHR, health is not only seen at the individual level but also from the family
social structure perspective, a government defined strategy for primary care [14].
Another important system design concept, in line with recent international recommendations for HIS
[15], is that all data models are either patient- or family-centered. This means that all health professionals
feed data into a model that enables information exchange to better support decisions focused either on
the individual or their family. For instance, leaving professional restriction on data privacy aside, let’s say
patient John D., a young teenager living with his parents initiates a fluoxetine treatment prescribed by
a local physician under complains of anxiety. From their conversations on a follow up examination, the
doctor decides to ask the patient to check with a psychiatrist. The psychiatrist then detects traces of acute
depression. Within the system the specialist has access to the community health agent notes (a type of
family health specialist who monthly surveys households around a primary care health center) who, couple
weeks back, checked on the family and reported that the household provider lost his/her job. With better
social and medical characterization of the problem, all three professionals can now provide a more accurate,
personalized, and systematic treatment to the teenager. Furthermore, caring for the family well-being as a
whole, and the long-term health of other family members, the physician requests that a social worker be
included in the case. This example, albeit simplistic, demonstrates the potential of a holistic approach to
public health, focused on prevention, and enabled by a city-wide EHR.
1.2 Drug dispensation in Blumenau
In order to provide readers some geographical context, Supplementary Figure 1 shows the location of Blu-
menau in Brazil as well as the city neighborhoods with their individual population density.
Blumenau
Population P(ΩN)
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Supplementary Figure 1: (left) Political map of Brazil with state borders. Arrow denotes city of Blumenau in the state of
Santa Catarina. (right) Political map of Blumenau with neighborhoods (N) annotated and mapped to city population, P (ΩN ).
Cartographic shapes from IBGE [7].
The monthly drug dispensation in the city of Blumenau can be seen in Supplemental Figure 2. We
conjecture that the smaller number of dispensed medication during summer months (Dec-Feb) are due to
a difference portion of the city population taking mandatory 30-days vacations yearly, which are usually
split in two 10-days vacations during the summer months, and another 10-days during the winter months.
The Atlantic Ocean coast, only a 40 minutes drive east, is a common destination for Blumenau citizens on
weekends and holidays. Carnival (Carnaval), which is usually held at the end of February, also draws many
citizens for a 1 week vacation on the coast.
3
05
10
15
20
25
30
Te
m
p.
 ◦ C
Jan 14 May 14 Sep 14 Jan 15 May 1550
60
70
80
90
100
110
α
 (i
n 
th
ou
sa
nd
s)
Drug intervals dispensed
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non shaded area) and average temperature in the same period. Grey area shows months in which the Pronto HIS was under
field deployment.
Since Brazil also has private health care and pharmaceutical systems, patients of the public system are
often thought to be from lower economical classes, a hypothesis we investigated.
Indeed, the proportion of Pronto patients for most age brackets in the four richest neighborhoods—
namely Jardim Blumenau, Bom Retiro, Victor Konder and Vila Formosa—are significantly smaller than in
other neighborhoods(t-test, p < 3−20). This strongly suggests that patients from the richest neighborhoods
use the public drug dispensation system much less than equivalent groups from other areas (see Supplemental
Figure 3).
The only exception to this pattern was found for females age 45-74 from Bom Retiro and Victor Konder
(2nd and 3rd richest neighborhoods, respectively), who, while using the system less than the same group
in other neighborhoods, do use it significantly more than those from the richest neighborhood, Jardim
Blumenau (t-test, p < 2−6). This suggests that these two higher-income neighborhoods have a population
of older women who uses the public health care system. This may be an interesting phenomenon warranting
further sociological studies.
1.3 Patient education
To place the education numbers acquired via Pronto system in perspective, we gathered data from the Atlas
Brasil Blumenau1, a United Nations Program for the Development of Brazil (PNUD).
In 2010 the city of Blumenau reported that the proportion of children age 5-6 in school was 88.41%.
For the same year the proportion of children age 11-13 attending the last years of elementary school was
90.41%. The proportion of teenagers age 15-17 having completed elementary school was 72,34%. And the
proportion of young adults age 18-20 who completed high school was 51.38%. Nationally these number were
91.12%, 84,86%, 57.24% and 41.01%, respectively. The average length of study for children in school age
was 10.81 years for Blumenau and 9.97 for the state of Santa Catarina. The number of adults, age 18 or
older, who completed elementary school was 65.88% for Blumenau and 54.92% for the state. Considering
adults age 25 or older: 2,13% were illiterate, 61,55% completed elementary school, 41,22% completed high
school and 15,49%, completed college. Nationally, these proportions are 11,82%, 50,75%, 35,83% and 11,27%,
respectively.
Below is the self-reported education distribution for unique patients of Pronto. Education level is re-
quested upon registration or profile update and no documents are required. However, staff in health centers
are trained to retrieve the best response from patients without their embarrassment—by displaying a card
with enumerated answers asking them to respond the according letter.
1http://atlasbrasil.org.br/2013/pt/perfil_m/blumenau_sc
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Supplementary Figure 3: Top. Neighborhood average income in Brazilian Reais (R$) [7]. Middle & bottom. Age-
neighborhood bins of male (middle; UN,y,g=M/ΩN,y,g=M ) and female (bottom; UN,y,g=F /ΩN,y,g=F ) patients registered in
Pronto with at least one drug dispensed and matched to DrugBank. Each bin is a probability-like value of patients normalized
by official census population data collected and defined by IBGE [7]. Green bins represent values above 1, meaning our data
has more patients than IBGE[7] census data. Conversely, cyan bins represent values where our data contains no patient.
E UE % Ac. % % Ac. %
Cant read/write 4,720 0.0356 0.0356 0.0773 0.0773
Can read/write a note 3,104 0.0234 0.0590 0.0508 0.1281
Incomplete elementary 28,557 0.2152 0.2741 0.4677 0.5958
Complete elementary 7,516 0.0566 0.3307 0.1231 0.7189
Incomplete high school 4,650 0.0350 0.3658 0.0762 0.7951
Complete high school 8,797 0.0663 0.4321 0.1441 0.9391
Incomplete college 1,654 0.0125 0.4445 0.0271 0.9662
Complete college 1,823 0.0137 0.4583 0.0299 0.9961
Espec./Residency 192 0.0014 0.4597 0.0031 0.9992
Masters 26 0.0002 0.4599 0.0004 0.9997
Doctoral 21 0.0002 0.4601 0.0003 1.0000
Not reported 71,662 0.5399 1.0000
Total 132,722 1.0000
Supplementary Table 1: Education level of Pronto patients
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E UE % Ac. % % Ac. %
Cant read/write 1,245 0.0134 0.0134 0.0257 0.0257
Can read/write a note 2,552 0.0274 0.0408 0.0528 0.0785
Incomplete elementary 23,983 0.2577 0.2985 0.4957 0.5742
Complete elementary 6,733 0.0723 0.3708 0.1392 0.7134
Incomplete high school 3,126 0.0336 0.4044 0.0646 0.7780
Complete high school 7,544 0.0811 0.4855 0.1559 0.9340
Incomplete college 1,233 0.0132 0.4987 0.0255 0.9594
Complete college 1,732 0.0186 0.5173 0.0358 0.9952
Espec./Residency 187 0.0020 0.5194 0.0039 0.9991
Masters 25 0.0003 0.5196 0.0005 0.9996
Doctoral 18 0.0002 0.5198 0.0004 1.0000
Not reported 44,690 0.4802 1.0000
Total 93,068 1.0000
Supplementary Table 2: Education level of Pronto patients age 25 or older
Supplementary Note 2 Computation details
This section describes variables used in the main manuscript. It also details computations in order to
facilitate replication. A quick symbol reference can be seen in Supplementary Note 3. All computations were
done in python using custom built scripts.
In our analysis, patients are denoted by u ∈ U and drugs by i, j ∈ D; Ui ∈ U is the subset of users
who were dispensed drug i, Du ⊆ D is the subset of drugs dispensed to patient u, and νu ≡ |Du| is the
number of distinct drugs dispensed to patient u. Drugs are dispensed to patients in administration intervals
a = (i, ts, tf ), where ts and tf are the start and end times (in days; t ∈ N) of drug administration, and
(tf − ts) represents the total length of administration, respectively. The total number of drug i intervals
dispensed to patient u is αui = |Aui |, where Aui ≡ {ai,un } is the set of administration intervals for patient u of
drug i in the data, with n = 1, . . . , αui .
Administration length. The total number of days patient u administered drug i (possibly over n
distinct dispensations) is then computed as
λui =
n∑
1
ai,un . (1)
Co-administration length. For each drug pair (i, j) administered to patient u,∀i, j ∈ Du, we identify
the possible length of administration overlap between administrations of both drugs, Aui ≡ {ai,un } and
Auj ≡ {aj,um }, assuming without loss of generality that ts,n ≤ ts,m, as
λui,j =
∑
an∈Aui
am∈Auj
{
(tf,n − ts,m) , iff (tf,n < ff,m)
(tf,m − ts,m) , otherwise
. (2)
Co-administrations. To be able to discriminate patients with a specific co-administration, and to
compute how many were prescribed such co-administration, we define
ψui,j =
(
λui,j > 0
)
, (3)
a logical variable measuring whether patient u had at least one day of co-administration between drug
pair (i, j); ψui,j ∈ {0, 1}. Then, the total number of co-administrations, per patient u or drug pair (i, j) is
calculated as
Ψu =
∑
i,j∈Du
ψui,j ≡ |UΨ| , Ψi,j =
∑
u∈U
ψui,j ≡ |UΨi,j | . (4)
Interactions. Next, we define a symmetrical binary map, also known as a symmetrical graph, ∆ :
D ×D → {0, 1} on set D indicating if a drug pair (i, j) ∈ D ×D has (δi,j = 1) a known DDI in DrugBank,
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or not (δi,j = 0). Then, to discriminate patients with a known DDI we define
ϕui,j =
(
ψui,j = 1 ∧ δi,j = 1
)
, (5)
a logical variable measuring whether patient u had at least one day of co-administration between drug
pair (i, j) and this drug pair is listed in DrugBank as a known DDI; ϕui,j ∈ {0, 1}. The total number of
co-administrations of known DDI, per patient u or drug pair (i, j) is calculated as
Φu =
∑
i,j∈Du
ϕui,j ≡ |UΦ| , Φi,j =
∑
u∈U
ϕui,j ≡ |UΦi,j | . (6)
Normalized interactions. To identify the drug pairs (i, j) with the largest “footprint” in the population,
we compute the pairs that are most co-administered in the population: those pairs that maximize |UΨi,j |. Out
of these, we are naturally most interested in the drug pairs that are known DDI and are most co-administered:
those that maximize |UΦi,j |. Two asymmetrical normalized versions of this measure are computed as
γΦi,j =
|UΦi,j |
|Ui| , γ
Φ
j,i =
|UΦi,j |
|Uj | , (7)
which conditions the number of users co-administered drug pair (i, j) on the number of users that are
administering either drug, i or j.
Normalized lengths. To obtain a normalized value of co-administration length, we also define
τui,j =
λui,j
λui + λ
u
j − λui,j
, (8)
where τui,j ∈ [0, 1], and can be thought of a probability—or a Jaccard measure where values indicate a
proximity [16–18]—of having drug pair (i, j) co-administered in relation to each drug’s individual length of
administration, for patient u.
Intuitively, if patient u always administers drugs i and j simultaneously, τui,j → 1. Conversely, drug
pairs with small co-administration overlap have τui,j → 0. A normalized measure for the entire population is
computed as
τΨi,j =
∑
u∈UΨi,j
τui,j
|UΨi,j |
, (9)
where this proximity measure defines a weighted graph TΦ [17] on set D where edges are τΨi,j ∈ [0, 1] and
link drugs that were co-administered in the population. τΨi,j is larger when drug pairs (i, j) tend to be
co-administered when either i or j is administered (correlated), and smaller otherwise (independent). To
obtain a subgraph TΦ, restricted to known DDI pairs, we compute τΨi,j × δi,j ; thus TΦ is a weighted version
of ∆. In practice, due to computational complexity, we only compute τΨi,j for drug pairs known to be a DDI
(ϕui,j > 0).
Drug classes. For drug pairs co-administered and known to be DDI, we gathered their respective drug
class hierarchy from Drugs.com [19]. In the main manuscript we used the top level of this hierarchy to
distinguish different types of drugs (i.e., cardiovascular agents, hormones, etc). For example, Fluoxetine2
has the following hierarchy: “Psychotherapeutic agents”, “Antidepressants”, and “Selective serotonin reuptake
inhibitors”, where the base class used was “Psychotherapeutic agents”.
2https://www.drugs.com/fluoxetine.html
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Supplementary Note 3 Notation and symbol reference
For quick reference, this chapter lists symbols used in the main manuscript and supplemental information.
symbol description
U, u Set of patients u ∈ U ⊂ N to whom at least one drug matched to
DrugBank was dispensed.
D, i Set of drugs i ∈ D ⊂ N available for dispensation in the public health
care system of Blumenau; Du ⊆ D is the subset of drugs administered
to patient u.
Aui ≡
{
ai,un
}
, an = (i, ts, tf )n Set of administration intervals an. Each interval is defined as a n-tuple
comprised of drug i and its administration start ts (the dispensation),
end time tf , and administration length tt = (tf − ts), where t ∈ N (in
days, n).
αui Number of drug intervals an (dispensations) to patient u. αui = |Aui |
νu Number of distinct drugs dispensed to patient u. νu ≡ |Du|
λui Administration length (in days) of drug i (across possibly multiple dis-
pensations) for patient u.
λui,j Co-administration length (in days) of drug pair (i, j) (across possibly
multiple dispensations) for patient u. See Supplementary Equation 2
for overlap computation.
∆, δi,j ∆ : D×D → 0, 1 is a symmetrical binary relation (symmetrical graph)
on set D, denoting the drug pairs having (δi,j = 1) a known DDI in
DrugBank [20], or not (δi,j = 0); δi,j = δj,i , δi,i = 0 (no self relation).
τui,j Normalized length of co-administration between drugs i and j for pa-
tient u. τui,j ∈ [0, 1] is a Jaccard measure between the number of
days drug pair (i, j) was co-administered (intersection) divided by the
number each drug, i and j was administered individually (union).
τui,j = λ
u
i,j/(λ
u
i + λ
u
j − λui,j)
Ω The total city population. Also ΩN and Ωy,g are population numbers
for a specific neighborhood N or for a certain age group y and gender
g, respectively.
Supplementary Table 3: Basic symbols used in the paper
symbol description
g Gender where g ∈ {M,F}.
y Age where y ∈ N. y can also be grouped into age intervals (e.g., y[0-4], y[5-9], ..., y[95-99],
y[>99]) following IBGE–Instituto Brasileiro de Geografia e Estatística [7] convention.
N Neighborhood N ∈ N in the city of Blumenau.
E Education levels N ∈ N following IBGE–Instituto Brasileiro de Geografia e Estatística [7]
convention.
s DDI severity based on Drugs.com [19] classification. s ∈ {major,moderate,minor, *, none}
Supplementary Table 4: Symbols used in indexing.
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symbol description
α Total number of administration intervals dispensed. α =
∑
u∈U,i∈Du α
u
i
ψui,j Logical variable denoting whether drug pair (i, j) was co-administered by patient u. ψui,j =
(λui,j > 0)
Ψu Number of distinct co-administrations for patient u. Ψu =
∑
i,j∈Du ψ
u
i,j
Ψi,j Number of distinct co-administrations between drug pair (i, j) for all patients. Ψi,j =∑
u∈Du ψ
u
i,j ≡ |Ui,j |
Ψ Total number of drug co-administrations. Ψ =
∑
u Ψ
u =
∑
i,j Ψi,j
ϕui,j Logical variable denoting whether drug pair (i, j) was co-administered to patient u and the
pair is listed in DrugBank as a known DDI. ϕui,j = (ψui,j > 0 ∧ δi,j = 1)
Φu Number of distinct co-administration for patient u known to be a DDI. Φu =
∑
i,j∈Du ϕ
u
i,j
Φi,j Number of distinct co-administrations known to be a DDI between drug pair (i, j), for all
patients. Φi,j =
∑
u∈U ϕ
u
i,j
Φ Total number of distinct drug interaction pairs. Φ =
∑
u Φ
u =
∑
i,j Φi,j
Uν>x Subset of patients who had at least x ∈ N distinct drugs administrations. Uν>x = {u ∈ U :
νu > x}.
UΨ Subset of patients who had at least 1 drug co-administration. UΨ = {u ∈ U : Ψu > 0}.
UΨi,j Subset of patients who were co-administered drug pair (i, j). UΨi,j ≡ {u ∈ U : ψui,j = 1}.
UΦ Subset of patients who had at least 1 known DDI. UΦ = {u ∈ U : Φu > 0}.
UΦi,j Subset of patients who were co-administered known DDI pair (i, j). UΦi,j ≡ {u ∈ U : ϕui,j =
1}.
Ug Subset of patients per gender g. Ug ≡ {u ∈ U : gender(u) = g}.
U [y1,y2] Subset of patients per age bracket [y1, y2]. U [y1,y2] ≡ {u ∈ U : age(u) ∈ [y1, y2]}.
UN Subset of patients per neighborhood N . UN ≡ {u ∈ U : neighborhood(u) ∈ N}.
UE Subset of patients per education level E. UE=∅ is the subset of patients who did not report
their education level.
γΨi,j , γ
Ψ
j,i Normalized number of patients that were co-administering drug pair (i, j). γΨi,j = |UΨi,j |/|Ui|
and γΨj,i = |UΨi,j |/|Uj |. Note γΨi,j 6= γΨj,i.
γΦi,j , γ
Φ
j,i Normalized number of patients that were co-administering drug pair (i, j), known to be a
DDI. γΦi,j = |UΦi,j |/|Ui| and γΦj,i = |UΦi,j |/|Uj |. Note γΦi,j 6= γΦj,i.
τΨi,j Normalized length of co-administration of drug pair (i, j), for all patients. τΨi,j =∑
u∈UΨi,j τ
u
i,j/|UΨi,j |
τΦi,j Normalized length of co-administration of drug pair (i, j), known to be a DDI, for all patients.
τΦi,j = τ
Ψ
i,j × δi,j
Supplementary Table 5: Administration, co-administration and interaction symbols
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symbol description
RRCF , RRCM Relative risk of co-administration for women and men, respectively. For com-
putation details see Supplementary Note 5.
RRIF , RRIM Relative risk of interaction for women and men, respectively. For computation
details see Supplementary Note 5.
PI(i) Probability of interaction, or the propensity of a drug i to be involved in a DDI
with all drugs it is co-administered with in the data. PI(i) =
∑
j Φi,j/
∑
j Ψi,j
Supplementary Table 6: Relative Risks and Probabilities
Supplementary Note 4 Drug Interactions
This section lists DDI found in the analysis. Data source for these interactions were retrieved from http://
wifo5-04.informatik.uni-mannheim.de/drugbank/. This dataset was last updated in 2011 and it contains
the DrugBank ID for each pair of drugs and a textual description of the interaction. The latest (version
5.0) version of the DrugBank database includes a much larger number of interaction although much of the
interaction at the top of the list could not be validated from a second source, namely Drugs.com [19]. Thus
we opted for a more conservative approach with fewer number of overall unique interaction that we could
attribute a severity score from a second data source.
From Drugs.com [19], the description of each severity score is as follow:
• Major : Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the
benefit.
• Moderate: Moderately clinically significant. Usually avoid combinations; use it only under special
circumstances.
• Minor : Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug,
take steps to circumvent the interaction risk and/or institute a monitoring plan.
Note that some interactions present in DrugBrank were not found in Drugs.com. These are marked as
None.
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rankΦ |UΦi,j | γΦi,j τΦi,j 〈λui,j〉 i j RRIFi,j severity
2 2117 0.18 0.23 53 ± 74 ASA Ibuprofen 1.42 Major
5 1190 0.19 0.45 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
7 892 0.14 0.20 56 ± 61 Fluconazole Simvastatin 2.63 Major
16 470 0.63 0.55 160 ± 133 Diltiazem Simvastatin 1.27 Major
23 257 0.16 0.42 123 ± 130 Imipramine Fluoxetine 3.08 Major
27 222 0.02 0.47 148 ± 139 Fluoxetine Lithium 1.79 Major
33 154 0.01 0.33 94 ± 92 Fluoxetine Nortriptyline 2.70 Major
36 148 0.14 0.49 168 ± 160 Haloperidol Lithium 1.31 Major
47 91 0.01 0.52 154 ± 142 Atenolol Diltiazem 1.19 Major
62 52 0.08 0.49 118 ± 114 Digoxin Amiodarone 0.56 Major
63 51 0.00 0.23 93 ± 90 Hydrochlorothiazide Lithium 2.90 Major
73 31 0.01 0.20 48 ± 66 Propranolol Salbutamol 6.61 Major
84 25 0.03 0.56 157 ± 136 Diltiazem Amiodarone 1.26 Major
85 24 0.00 0.05 3 ± 2 Diclofenac Warfarin 0.84 Major
89 23 0.03 0.47 152 ± 143 Diltiazem Propranolol 2.01 Major
89 23 0.00 0.16 36 ± 44 Fluconazole Haloperidol 1.33 Major
91 22 0.00 0.07 9 ± 4 Ciprofloxacin Warfarin 1.02 Major
93 21 0.01 0.08 10 ± 6 Tobramycin Furosemide 3.01 Major
95 19 0.00 0.07 10 ± 7 Ciprofloxacin Aminophylline 1.21 Major
97 18 0.00 0.13 33 ± 44 Fluconazole Warfarin 0.89 Major
Supplementary Table 11: Top 20 major DDI pairs (i, j) by rank of |UΦi,j |, the number of patients affects by the DDI
(1st and 2nd columns, respectively). The normalized drug pair footprint in the population (γΦi,j) as well as the normalized
co-administration length (τΦi,j), are shown in columns 3 and 4, respectively. Mean (± s.d.) co-administration length, 〈λui,j〉, is
shown in column 5 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and 7. The relative
gender risk of DDI pair co-administration, RRIFi,j , is shown in column 8. DDI severity classification, according to Drugs.com,
shown in column 9.
rankp(γ) γΦi,j γ
Φ
j,i |UΦi,j | 〈λui,j〉 i j RRIFi,j severity
1 0.50 0.61 524 243 ± 188 Haloperidol Biperiden 0.62 Moderate
2 0.59 0.12 385 155 ± 125 Digoxin Furosemide 0.61 Moderate
3 0.19 0.36 5078 102 ± 95 Omeprazole Clonazepam 2.28 Moderate
4 0.10 0.50 1249 141 ± 124 ASA Glyburide 0.89 Moderate
5 0.42 0.14 272 140 ± 114 Digoxin Spironolactone 0.58 Minor
6 0.63 0.02 470 160 ± 133 Diltiazem Simvastatin 1.27 Major
7 0.27 0.15 173 109 ± 96 Digoxin Carvedilol 0.53 Moderate
8 0.04 0.44 496 103 ± 87 ASA Gliclazide 0.78 None
9 0.04 0.31 999 87 ± 86 Omeprazole Diazepam 1.21 Moderate
9 0.19 0.09 1190 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
11 0.14 0.16 148 168 ± 160 Haloperidol Lithium 1.31 Major
12 0.07 0.22 535 152 ± 132 Atenolol Glyburide 1.22 Moderate
13 0.18 0.08 186 142 ± 156 Haloperidol Carbamazepine 0.62 Moderate
14 0.18 0.06 2117 53 ± 74 ASA Ibuprofen 1.42 Major
14 0.20 0.04 1460 54 ± 77 Atenolol Ibuprofen 1.88 Moderate
16 0.02 0.24 222 148 ± 139 Fluoxetine Lithium 1.79 Major
17 0.03 0.18 201 107 ± 95 Atenolol Gliclazide 1.09 None
18 0.01 0.26 154 94 ± 92 Fluoxetine Nortriptyline 2.70 Major
19 0.28 0.00 149 115 ± 109 Phenytoin Omeprazole 0.80 Moderate
20 0.03 0.17 377 143 ± 138 Fluoxetine Carbamazepine 0.98 Moderate
Supplementary Table 12: Top 20 known DDI pairs (i, j) by rank product (1st column) of the ranks of γΦi,j and γ
Φ
j,i, the
normalized drug pair footprint in the population (1st, 2nd and 3rd columns, respectively). The number of patients affected
by the drug pair, |UΦi,j |, is shown in column 4. Mean (± s.d.) co-administration length, 〈λui,j〉, is shown in column 5 (in
days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and 7. The relative gender risk of DDI pair
co-administration, RRIFi,j , is shown in column 8. DDI severity classification, according to Drugs.com, shown in column 9; DDIs
or drugs not found in Drugs.com are labeled as None or *, respectively.
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rankτ τΦi,j |UΦi,j | 〈λui,j〉 i j RRIFi,j severity
1 0.70 524 243 ± 188 Haloperidol Biperiden 0.62 Moderate
2 0.60 1249 141 ± 124 ASA Glyburide 0.89 Moderate
3 0.60 385 155 ± 125 Digoxin Furosemide 0.61 Moderate
4 0.58 535 152 ± 132 Atenolol Glyburide 1.22 Moderate
5 0.57 95 140 ± 126 Propranolol Glyburide 1.61 Moderate
6 0.56 25 157 ± 136 Diltiazem Amiodarone 1.26 Major
7 0.56 13 122 ± 113 Propranolol Methyldopa 8.50 Major
8 0.55 470 160 ± 133 Diltiazem Simvastatin 1.27 Major
9 0.55 5 82 ± 86 Propranolol Aminophylline 1.06 Major
10 0.55 272 140 ± 114 Digoxin Spironolactone 0.58 Minor
11 0.53 2 288 ± 213 Phenytoin Medroxyproges. Ac. inf Moderate
12 0.52 91 154 ± 142 Atenolol Diltiazem 1.19 Major
13 0.51 1 31 ± 0 Phenytoin Sulfadiazine 0.00 Moderate
14 0.50 90 161 ± 157 Imipramine Carbamazepine 1.35 Moderate
15 0.50 377 143 ± 138 Fluoxetine Carbamazepine 0.98 Moderate
16 0.49 226 151 ± 145 Amitriptyline Carbamazepine 0.99 Moderate
17 0.49 52 118 ± 114 Digoxin Amiodarone 0.56 Major
18 0.49 1 179 ± 0 Phenytoin Levonorgestrel inf Major
18 0.49 1 179 ± 0 Phenytoin Ethinyl Estradiol inf Major
20 0.49 148 168 ± 160 Haloperidol Lithium 1.31 Major
Supplementary Table 13: Top 20 known DDI pairs (i, j) by rank of τΦi,j , the normalized co-administration length (1
st and
2nd columns, respectively). The number of patients affected by the drug pair, |UΦi,j |, is shown in column 3. Mean (± s.d.)
co-administration length, 〈λui,j〉, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug names are shown in
columns 5 and 6. The relative gender risk of DDI pair co-administration, RRIFi,j , shown in column 7. DDI severity classification,
according to Drugs.com, shown in column 8; DDIs or drugs not found in Drugs.com are labeled as None or *, respectively.
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4.1 Interactions per severity
In this section, Supplementary Table 14 shows the number of individual interactions and unique users, both
per severity of interaction.
Note that some interactions present in DrugBrank were not found in Drugs.com. These are marked as
None. The drug Fenoterol (brand name Berotec in Brazil) was not found in Drugs.com. These interactions
were summed separately and are shown with an asterisk (* ).
severity s Φs |UΦs | |UΦs |/|U | |UΦs |/|Ω|
Major 5,968 (22.50%) 5,224 3.94% 1.54%
Moderate 18,335 (69.13%) 12,711 9.58% 3.75%
Minor 542 (02.04%) 528 0.40% 0.16%
None 1,489 (05.61%) 1,314 0.99% 0.39%
* 190 (00.72%) 179 0.13% 0.05%
Total 26,524 (100%) 19,956 -% -%
Supplementary Table 14: The 2nd column lists the numbers of interactions, Φs, per DDI severity class (1st column);
percentages of interactions per class are shown in parenthesis. Drugs or interactions identified in DrugBank but not present in
Drugs.com are tallied as None. Interactions for Berotec tallied as *. The 3rd column lists the number of patients affected by
at least one interaction |UΦs |, per DDI severity. Fourth and fifth columns lists the proportion of patients in each DDI severity
class for the Pronto system and the entire Blumenau populations, respectively. Notice that the same patient may have been
administered DDI of more than one severity type.
4.2 Interactions per gender
In this section, Supplementary Table 15 shows the number of individual interactions and unique users per
gender.
gender g Φg |UΦ,g| |UΦ,g|/|U | |UΦ,g|/|Ω|
Male 8,100 (30.54%) 4,793 3.61% 1.41%
Female 18,424 (69.46%) 10,734 8.09% 3.17%
Total 26,524 (100%) 15,527 11.70% 4.58%
Supplementary Table 15: The 2nd column lists the numbers of interactions, Φ, per gender (1st column); percentages of
interactions per gender shown in parenthesis. The 3rd column lists the number of patients affected by at least one interaction
per gender, |UΦ,g |. The 4th and 5th columns show the proportion of patients in each gender for the Pronto system and entire
Blumenau populations, respectively.
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4.3 Interactions per age
Supplementary Table 16 shows the number of individual interaction and unique users per age group.
age y Φy |UΦ,y| |UΦ,y|/|U | |UΦ,y|/|Ω|
00-04 23 (0.09%) 20 0.02% 0.01%
05-09 7 (0.03%) 7 0.01% 0.00%
10-14 29 (0.11%) 25 0.02% 0.01%
15-19 172 (0.65%) 139 0.10% 0.04%
20-24 311 (1.17%) 237 0.18% 0.07%
25-29 433 (1.63%) 301 0.23% 0.09%
30-34 771 (2.91%) 525 0.40% 0.15%
35-39 1,097 (4.14%) 687 0.52% 0.20%
40-44 1,581 (5.96%) 1,023 0.77% 0.30%
45-49 2,332 (8.79%) 1,426 1.07% 0.42%
50-54 3,128 (11.79%) 1,868 1.41% 0.55%
55-59 3,447 (13.00%) 1,956 1.47% 0.58%
60-64 3,508 (13.23%) 2,006 1.51% 0.59%
65-69 3,254 (12.27%) 1,794 1.35% 0.53%
70-74 2,417 (9.11%) 1,311 0.99% 0.39%
75-79 1,978 (7.46%) 1,057 0.80% 0.31%
80-84 1,143 (4.31%) 638 0.48% 0.19%
85-89 620 (2.34%) 349 0.26% 0.10%
90-94 205 (0.77%) 117 0.09% 0.03%
95-99 49 (0.18%) 27 0.02% 0.01%
>99 19 (0.07%) 14 0.01% 0.00%
Total 26,524 (100%) 15,527 11.70% 4.58%
Supplementary Table 16: The 2nd column lists the numbers of interactions, Φy , per age range (1st column); percentages of
interactions per age range shown in parenthesis. The 3rd column lists the number of patients affected by at least one interaction
per age range, |UΦ,y |. The 4th and 5th columns show the proportion of patients in each age range from the Pronto system and
entire Blumenau populations, respectively.
4.4 Interaction per age and gender
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Supplementary Figure 4: The joint probability a patient was dispensed at least one drug P (Uν>0,y,g), had co-
administrations P (UΨ,y,g), or had a DDI P (UΦ,y,g), given age range ([y1, y2]) and gender (g), are shown in blue, orange
and red lines, respectively. Values for age group y ≥ 90 were aggregated for plotting. Population distribution for Blumenau
P (Ωy,g) is shown as a green fill. A Kolmogorov-Smirnov test cannot reject the hypothesis that both the female and male
distribution of patients with at least one co-administration known to be DDI (UΦ,y,g) are drawn from the same underlying
continuous distribution (KS = .3810, p-value = .0706).
18
00
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
>8
00
2
4
6
8
10
12
ν
u
Administration
g=M
g=F
00
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
>8
010
0
10
20
30
40
50
60
Ψ
u
Co-administration
g=M
g=F
00
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
-7
9
>8
00.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Φ
u
Interaction
g=M
g=F
Supplementary Figure 5: Left. Mean number of drugs dispensed (νu) to patients in each age group. Middle. Mean
number of drug pairs co-administered (Ψu) by patients in each age group. Right. Mean number of drug pairs known to be a
DDI (Φu) co-administered by patients in each age group. Numbers for male and female patients shown in lighter and darker
colors, respectively. In all plots vertical bars denote the standard deviation.
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Supplementary Figure 6: Left. Absolute number of patients with at least one co-administration per age group, |UΨ,[y1,y2]|.
Right. Absolute number of patients with at least one co-administration per age group and gender, |UΨ,[y1,y2],g |.
Supplementary Note 5 Risk and Relative Risk measures
Risk and Relative Risk measures are computed based on the number of patients in specific groups. Here we
detail the computation of all measures used throughout the main manuscript.
The relative risk of co-administration and interaction for women, are computed as
RRCF =
P (Ψu > 0 |u ∈ UF)
P (Ψu > 0 |u ∈ UM) =
|UΨ,F | /|UF|
|UΨ,M | /|UM| ; RRI
F =
P (Φu > 0 |u ∈ UF)
P (Φu > 0 |u ∈ UM) =
|UΦ,F | /|UF|
|UΦ,M | /|UM| . (10)
Similarly, RRCM = 1/RRCF and RRIM = 1/RRIF . In the main manuscript we mentioned the computa-
tion of RRIF without contraceptive drugs. The drug removed in this computation were Ethinyl Estradiol,
Estradiol, Norethisterone, Levonorgestrel and Estrogens Conjugated.
The relative risk of an interaction at a certain DDI severity level, s ∈ {major,moderate,minor,none, *},
given gender, is computed as
RRIFs =
P (Φus > 0 |u ∈ UF)
P (Φus > 0 |u ∈ UM)
=
|UΦ,Fs |/|UF|
|UΦ,Ms | |UM|
. (11)
The relative risk of an interaction between two drugs, given gender, is computed as
RRIFi,j =
P (Φui,j > 0 |u ∈ UF)
P (Φui,j > 0 |u ∈ UM)
=
|UΦ,Fi,j |/|UF|
|UΦ,Mi,j |/|UM |
. (12)
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The relative risk of co-administration and interaction, given number of dispensed drugs, are computed as
RRCν=x =
P (Ψu |u ∈ Uν=x)
P (Ψy |u ∈ Uν=2) =
|UΨ,ν=x|/|Uν=x|
|UΨ,ν=2|/|Uν=2| ; RRI
ν=x =
P (Φu |u ∈ Uν=x)
P (Φu |u ∈ Uν=2) =
|UΦ,ν=x|/|Uν=x|
|UΦ,ν=2|/|Uν=2| .
(13)
The risk of co-administration and interaction, given age group, are computed as
RC [y1,y2] =
P (Ψu > 0 |u ∈ U [y1,y2])
P (νu ≥ 2 |u ∈ U [y1,y2]) =
|UΨ,[y1,y2]|
|Uν≥2,[y1,y2]| ; RI
[y1,y2] =
P (Φu > 0 |u ∈ U [y1,y2])
P (Ψu > 0 |u ∈ U [y1,y2]) =
|UΨ,[y1,y2]|
|UΦ,[y1,y2]| .
(14)
Note RC [y1,y2] and RI [y1,y2] can be also interpreted as probabilities. Similarly, we also compute the risk
of co-administration and interaction, per age group and gender as
RCg,[y1,y2] =
P (Ψu > 0 |u ∈ Ug,[y1,y2])
P (νu ≥ 2 |u ∈ Ug,[y1,y2]) =
|UΨ,g,[y1,y2]|
|Uν≥2,g,[y1,y2]| ; RI
g,[y1,y2] =
P (Φu > 0 |u ∈ Ug,[y1,y2])
P (Ψu > 0 |u ∈ Ug,[y1,y2]) =
|UΨ,g,[y1,y2]|
|UΦ,g,[y1,y2]| .
(15)
5.1 Relative Risk per gender
g |Ug| |Uν≥2| |UΨ,g| |UΦ,g| RRCF RRIF
Male 55,032 41,922 39,723 4,793 1.0000 1.0000
Female 77,690 62,889 59,738 10,734 1.0653 1.5864
Supplementary Table 17: Absolute number of patients and relative risk measures per gender (g, 1st column). Columns 2
through 5 lists, per gender, absolute numbers of: patients (|Ug |), patients with at least 2 administrations (|Uν≥2|), patients
with at least one co-administration (|UΨ,g |), and patients with at least one known DDI co-administration (|UΦ,g |). Relative
Risk for women for both co-administration (RRCF ) and known DDI co-administration (RRIF ) are listed in columns 6 and 7,
respectively.
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rankp(RRI, UF) |UΦ,M | |UΦ,F | 〈λui,j〉 i j RRIFi,j severity
1 (1,49) 0 30 10 ± 3 Clavulanate Ethinyl Estradiol inf None
2 (1,51) 0 27 8 ± 7 Prednisone Estradiol inf Moderate
2 (1,51) 0 27 11 ± 6 Doxycycline Ethinyl Estradiol inf Moderate
4 (1,57) 0 22 19 ± 28 Estrogens Conj. Prednisone inf Moderate
5 (1,71) 0 13 35 ± 26 Carbamazepine Ethinyl Estradiol inf Major
5 (1,71) 0 13 35 ± 26 Levonorgestrel Carbamazepine inf Major
7 (76,1) 1204 3874 102 ± 95 Omeprazole Clonazepam 2.28 Moderate
8 (1,83) 0 9 72 ± 128 Carbamazepine Norethisterone inf Major
9 (1,89) 0 7 11 ± 4 Doxycycline Iron (II) Sulfate inf Moderate
10 (1,94) 0 5 162 ± 120 Medroxyproges. Ac. Phenobarbital inf Moderate
10 (1,94) 0 5 10 ± 6 Prednisolone Ethinyl Estradiol inf Moderate
12 (1,98) 0 4 40 ± 29 Levonorgestrel Phenobarbital inf Major
12 (1,98) 0 4 10 ± 2 Estrogens Conj. Prednisolone inf Moderate
14 (1,102) 0 3 97 ± 94 Estrogens Conj. Phenobarbital inf Moderate
14 (1,102) 0 3 40 ± 57 Methyldopa Levodopa inf Minor
14 (1,102) 0 3 45 ± 43 Medroxyproges. Ac. Warfarin inf None
14 (1,102) 0 3 40 ± 19 Digoxin Verapamil inf Moderate
14 (1,102) 0 3 53 ± 16 Ethinyl Estradiol Phenobarbital inf Major
14 (1,102) 0 3 136 ± 117 Ethinyl Estradiol Aminophylline inf Moderate
20 (1,111) 0 2 23 ± 11 Doxycycline Phenobarbital inf Moderate
20 (1,111) 0 2 79 ± 30 Norethisterone Phenobarbital inf Major
20 (1,111) 0 2 288 ± 213 Phenytoin Medroxyproges. Ac. inf Moderate
20 (1,111) 0 2 62 ± 53 Phenytoin Norethisterone inf Major
20 (1,111) 0 2 62 ± 53 Phenytoin Estradiol inf Moderate
20 (1,111) 0 2 79 ± 30 Estradiol Phenobarbital inf Moderate
20 (1,111) 0 2 2 ± 0 Timolol Fenoterol inf *
20 (1,111) 0 2 31 ± 0 Timolol Aminophylline inf Major
20 (1,111) 0 2 6 ± 1 Estradiol Prednisolone inf Moderate
29 (1,124) 0 1 117 ± 0 Haloperidol Methyldopa inf Moderate
29 (1,124) 0 1 2 ± 0 Atenolol Epinephrine inf Moderate
29 (1,124) 0 1 12 ± 0 Timolol Methyldopa inf Major
29 (1,124) 0 1 29 ± 0 Phenytoin Estrogens Conj. inf Moderate
29 (1,124) 0 1 2 ± 0 Erythromycin Diazepam inf Moderate
29 (1,124) 0 1 4 ± 0 Erythromycin Aminophylline inf Moderate
29 (1,124) 0 1 179 ± 0 Phenytoin Ethinyl Estradiol inf Major
29 (1,124) 0 1 179 ± 0 Phenytoin Levonorgestrel inf Major
29 (1,124) 0 1 15 ± 0 Phenytoin Doxycycline inf Moderate
29 (1,124) 0 1 9 ± 0 Erythromycin Fluoxetine inf Moderate
39 (104,2) 706 1411 53 ± 74 ASA Ibuprofen 1.42 Major
40 (59,4) 198 992 127 ± 127 Amitriptyline Fluoxetine 3.55 Major
41 (83,3) 400 1060 54 ± 77 Atenolol Ibuprofen 1.88 Moderate
42 (75,5) 189 703 56 ± 61 Fluconazole Simvastatin 2.63 Major
43 (62,7) 108 519 46 ± 54 Fluconazole Clonazepam 3.40 None
44 (61,9) 86 415 44 ± 62 Propranolol Ibuprofen 3.42 Moderate
45 (52,12) 46 309 86 ± 84 Fluoxetine Propranolol 4.76 Moderate
46 (38,17) 1 178 10 ± 6 Ethinyl Estradiol Amoxicillin 126.09 Moderate
47 (117,6) 369 630 87 ± 86 Omeprazole Diazepam 1.21 Moderate
48 (53,14) 38 246 66 ± 57 Levothyroxine Iron (II) Sulfate 4.59 Moderate
49 (81,10) 134 366 52 ± 75 Furosemide Ibuprofen 1.93 Moderate
49 (54,15) 35 210 42 ± 40 Fluconazole Amitriptyline 4.25 Moderate
51 (110,8) 265 487 30 ± 50 ASA Dexamethasone 1.30 Moderate
52 (64,16) 48 209 123 ± 130 Imipramine Fluoxetine 3.08 Major
53 (47,23) 12 104 9 ± 7 Norfloxacin Iron (II) Sulfate 6.14 Moderate
54 (41,27) 7 95 4 ± 4 Diclofenac Alendronate 9.61 Moderate
55 (39,29) 1 83 15 ± 26 Prednisone Ethinyl Estradiol 58.79 Moderate
56 (115,11) 197 338 152 ± 132 Atenolol Glyburide 1.22 Moderate
57 (40,35) 2 61 33 ± 28 Methyldopa Iron (II) Sulfate 21.60 Moderate
58 (71,20) 31 124 68 ± 80 Amitriptyline Salbutamol 2.83 Moderate
59 (112,13) 168 302 160 ± 133 Diltiazem Simvastatin 1.27 Major
60 (84,18) 63 159 148 ± 139 Fluoxetine Lithium 1.79 Major
Supplementary Table 18: Top 60 known DDI pairs (i, j) most imbalanced for females, sorted by rank product (1st column;
individual rank in parenthesis) of RRIFi,j , the relative gender risk of DDI pair co-administration, and |UΦ,F |, the number of
women affected by the DDI (7nd and 3rd columns, respectively). The number of men (|UΦ,M |) affected is shown in column
2. Mean (± s.d.) co-administration length, 〈λui,j〉, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug
names are shown in columns 5 and 6. DDI severity classification, according to Drugs.com, shown in column 8; DDIs or drugs
not found in Drugs.com are labeled as None or *, respectively.
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rankp(RRI, UM) |UΦ,M | |UΦ,F | 〈λui,j〉 i j RRIMi,j severity
1 (1,32) 4 0 72 ± 61 Atenolol Verapamil inf Major
2 (1,38) 3 0 185 ± 98 Phenytoin Levodopa inf Moderate
3 (20,2) 280 244 243 ± 188 Haloperidol Biperiden 1.62 Moderate
3 (40,1) 553 696 141 ± 124 ASA Glyburide 1.12 Moderate
5 (1,43) 1 0 124 ± 0 Carbamazepine Verapamil inf Major
5 (1,43) 1 0 6 ± 0 Erythromycin Carbamazepine inf Major
5 (1,43) 1 0 31 ± 0 Phenytoin Sulfadiazine inf Moderate
8 (18,5) 207 178 155 ± 125 Digoxin Furosemide 1.64 Moderate
9 (13,9) 99 74 109 ± 96 Digoxin Carvedilol 1.89 Moderate
10 (8,15) 37 10 135 ± 109 Allopurinol Warfarin 5.22 Moderate
11 (41,3) 262 347 48 ± 93 Prednisone ASA 1.07 Moderate
12 (33,4) 236 260 103 ± 87 ASA Gliclazide 1.28 None
13 (17,8) 149 123 140 ± 114 Digoxin Spironolactone 1.71 Minor
14 (6,24) 10 1 57 ± 46 Methylphenidate Carbamazepine 14.12 None
15 (21,9) 99 87 142 ± 156 Haloperidol Carbamazepine 1.61 Moderate
16 (7,32) 4 1 107 ± 123 Phenytoin Amiodarone 5.65 Moderate
17 (12,22) 16 11 10 ± 6 Phenytoin Ciprofloxacin 2.05 Moderate
18 (16,17) 29 23 118 ± 114 Digoxin Amiodarone 1.78 Major
19 (46,6) 158 219 143 ± 138 Fluoxetine Carbamazepine 1.02 Moderate
20 (11,26) 9 6 20 ± 17 Carvedilol Fenoterol 2.12 *
21 (42,7) 156 208 110 ± 106 Carbamazepine Simvastatin 1.06 Moderate
22 (9,38) 3 1 62 ± 44 Phenobarbital Aminophylline 4.24 Moderate
23 (19,20) 23 20 144 ± 153 Phenytoin Diazepam 1.62 Moderate
24 (15,26) 9 7 94 ± 83 Phenytoin Furosemide 1.82 Minor
25 (14,28) 8 6 5 ± 3 Doxycycline Amoxicillin 1.88 Moderate
26 (34,12) 70 79 115 ± 109 Phenytoin Omeprazole 1.25 Moderate
27 (10,41) 2 1 9 ± 4 Phenytoin Prednisolone 2.82 Moderate
28 (22,21) 20 19 82 ± 64 Gliclazide Carvedilol 1.49 None
29 (36,13) 55 68 31 ± 43 Ibuprofen Carvedilol 1.14 Moderate
30 (30,16) 35 36 169 ± 151 Phenytoin Fluoxetine 1.37 Moderate
31 (48,11) 94 132 151 ± 145 Amitriptyline Carbamazepine 1.01 Moderate
32 (32,17) 29 31 49 ± 95 Prednisone Warfarin 1.32 Moderate
33 (31,19) 28 29 96 ± 96 Glyburide Carvedilol 1.36 Moderate
34 (45,14) 50 67 126 ± 127 Digoxin Hydrochlorothiazide 1.05 Moderate
35 (23,30) 7 7 9 ± 7 Furosemide Gentamicin 1.41 Major
36 (24,32) 4 4 82 ± 54 Carbamazepine Aminophylline 1.41 Moderate
36 (24,32) 4 4 67 ± 36 Diltiazem Carbamazepine 1.41 Major
38 (35,23) 11 13 3 ± 2 Diclofenac Warfarin 1.19 Major
39 (24,41) 2 2 4 ± 3 Doxycycline Clavulanate 1.41 None
40 (24,43) 1 1 102 ± 110 Propranolol Verapamil 1.41 Major
40 (24,43) 1 1 274 ± 218 Digoxin Propylthiouracil 1.41 Moderate
40 (24,43) 1 1 2 ± 0 Phenytoin Hydrocortisone 1.41 Moderate
43 (37,28) 8 10 33 ± 44 Fluconazole Warfarin 1.13 Major
44 (47,24) 10 14 100 ± 85 Carbamazepine Warfarin 1.01 Moderate
45 (37,32) 4 5 51 ± 91 Timolol Salbutamol 1.13 Major
45 (37,32) 4 5 7 ± 1 Prednisolone Phenobarbital 1.13 Moderate
47 (42,31) 6 8 88 ± 71 Phenytoin Warfarin 1.06 Moderate
48 (42,38) 3 4 62 ± 97 Phenytoin Trimethoprim 1.06 Moderate
Supplementary Table 19: All 48 known DDI pairs (i, j) most imbalaced for males, sorted by rank product (1st column;
individual rank in parenthesis) of RRIMi,j , the relative gender risk of DDI pair co-administration, and |UΦ,M |, the number of
men affected by the DDI (7nd and 2rd columns, respectively). The number of women (|UΦ,F |) affected is shown in column
3. Mean (± s.d.) co-administration length, 〈λui,j〉, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug
names are shown in columns 5 and 6. DDI severity classification, according to Drugs.com, shown in column 8; DDIs or drugs
not found in Drugs.com are labeled as None or *, respectively.
RRIgi,j ≥ x |DΦ,F | |DΦ,M | ΦF ΦM ΦFmajor ΦMmajor
1 68 46 133 48 31 10
2 56 17 80 12 21 3
3 49 13 65 9 16 3
4 45 13 58 9 13 3
5 38 11 49 8 13 3
6 36 8 47 6 13 3
7 35 8 45 6 12 3
8 32 8 42 6 12 3
9 31 8 41 6 11 3
10 29 8 40 6 11 3
Supplementary Table 20: Number and proportions of drugs and interactions at increasing level of relative gender risk of
DDI pair co-administration, RRIgi,j > x (1
st column). Number of drugs by gender, is shown in columns 2 and 3. Number of
drug pairs known to be a DDI, by gender, is shown in columns 4 and 5. Number of drug pairs, known to be a major DDI, by
gender, is shown in columns 6 and 7. See also Supplementary Table 21.
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RRIgi,j ≥ x |UΦ,F | |UΦ,M | |UΦ,Fmajor| |UΦ,Mmajor| |U
Φ,F |
|UF |
|UΦ,M |
|UM |
|UΦ,F
major
|
|UF |
|UΦ,M
major
|
|UM |
1 9,836 2,010 3,747 69 12.66% 03.65% 04.82% 00.13%
2 7,089 91 2,060 6 09.12% 00.17% 02.65% 00.01%
3 3,327 64 1,255 6 04.28% 00.12% 01.62% 00.01%
4 1,589 64 73 6 02.05% 00.12% 00.09% 00.01%
5 775 61 73 6 01.00% 00.11% 00.09% 00.01%
6 744 20 73 6 00.96% 00.04% 00.09% 00.01%
7 615 20 45 6 00.79% 00.04% 00.06% 00.01%
8 547 20 45 6 00.70% 00.04% 00.06% 00.01%
9 536 20 33 6 00.69% 00.04% 00.04% 00.01%
10 441 20 33 6 00.57% 00.04% 00.04% 00.01%
Supplementary Table 21: Number and proportions of affected patients at increasing level of relative gender risk of DDI pair
co-administration, RRIgi,j > x (1
st column). Number of patients by gender, is shown in columns 2 and 3. Number of patients
by gender and major DDI, is shown in columns 4 and 5. The relative proportion of affected patients in relation to the Pronto
population is shown in columns 6 through 9. See also Supplementary Table 20.
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5.2 Relative Risk per severity
severity s |UΦ,Ms | |UΨ,Fs | RRIFs
Major 1,433 3791 1.8739
Moderate 3,951 8760 1.5705
Minor 247 281 0.8059
None 409 905 1.5674
* 39 140 2.5428
Supplementary Table 22: Absolute number of patients and relative risk measures per gender (g) and severity score (s, 1st
column). Columns 2 and 3 lists absolute number of males (g = M) and females (g = F ) affected by at least one DDI for each
severity score, respectively. Column 4 lists the relative risk of interaction given a specific severity score and gender. DDIs or
drugs not found in Drugs.com are labeled as None or *, respectively Notice that the same patient may have been administered
DDI of more than one severity type.
5.3 Risk Measures per age
[y1, y2] |U [y1,y2]| |Uν≥2,[y1,y2]| |UΨ,[y1,y2]| |UΦ,[y1,y2]| RC[y1,y2] RI[y1,y2]
00-04 8,946 7,195 6,810 20 0.9465 0.0029
05-09 6,390 4,688 4,362 7 0.9305 0.0016
10-14 5,631 3,794 3,507 25 0.9244 0.0071
15-19 8,305 6,094 5,705 139 0.9362 0.0244
20-24 10,382 7,819 7,334 237 0.9380 0.0323
25-29 9,725 7,305 6,835 301 0.9357 0.0440
30-34 9,100 6,787 6,386 525 0.9409 0.0822
35-39 8,844 6,696 6,259 687 0.9347 0.1098
40-44 9,184 7,043 6,615 1,023 0.9392 0.1546
45-49 10,085 8,039 7,610 1,426 0.9466 0.1874
50-54 10,650 8,617 8,200 1,868 0.9516 0.2278
55-59 9,236 7,686 7,386 1,956 0.9610 0.2648
60-64 8,179 7,049 6,801 2,006 0.9648 0.2950
65-69 6,315 5,572 5,444 1,794 0.9770 0.3295
70-74 4,412 3,916 3,843 1,311 0.9814 0.3411
75-79 3,398 3,042 2,968 1,057 0.9757 0.3561
80-84 2,129 1,909 1,874 638 0.9817 0.3404
85-89 1,174 1,029 1,007 349 0.9786 0.3466
90+ 637 531 515 158 0.9699 0.3068
Supplementary Table 23: Absolute number of patients and risk measures per age range ([y1, y2], 1st column). Columns
2 through 5 lists, per age range, absolute numbers of: patients (|U [y1,y2]|), patients with at least 2 drug administrations
(|Uν≥2,[y1,y2]|), patients with at least one co-administration (|UΨ,[y1,y2]|), and patients with at least one known DDI co-
administration (|UΦ,[y1,y2]|). Per age range risk for both co-administration (RC[y1,y2]) and known DDI co-administration
(RI[y1,y2]) are listed in columns 6 and 7, respectively.
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[y1, y2] |UM,[y1,y2]| |Uν≥2,M,[y1,y2]| |UΨ,M,[y1,y2]| |UΦ,M,[y1,y2]| RCM,[y1,y2] RIM,[y1,y2]
00-04 4,537 3,664 3,473 8 0.9479 0.0023
05-09 3,319 2,416 2,239 3 0.9267 0.0013
10-14 2,932 1,926 1,776 14 0.9221 0.0079
15-19 3,518 2,390 2,247 33 0.9402 0.0147
20-24 4,204 3,020 2,838 76 0.9397 0.0268
25-29 4,066 2,890 2,708 99 0.9370 0.0366
30-34 3,692 2,641 2,500 1,68 0.9466 0.0672
35-39 3,428 2,488 2,317 1,90 0.9313 0.0820
40-44 3,504 2,559 2,394 2,79 0.9355 0.1165
45-49 3,945 3,043 2,892 4,17 0.9504 0.1442
50-54 4,142 3,219 3,048 5,25 0.9469 0.1722
55-59 3,638 2,953 2,829 6,06 0.9580 0.2142
60-64 3,257 2,731 2,622 6,26 0.9601 0.2387
65-69 2,525 2,197 2,148 6,45 0.9777 0.3003
70-74 1,729 1,494 1,461 4,27 0.9779 0.2923
75-79 1,303 1,162 1,127 3,44 0.9699 0.3052
80-84 718 649 637 1,86 0.9815 0.2920
85-89 361 312 304 98 0.9744 0.3224
90+ 214 168 163 49 0.9702 0.3006
Supplementary Table 24: Absolute number of male patients and risk measures per age range ([y1, y2], 1st column). Columns
2 through 5 lists, per age range, absolute numbers of: male patients (|Uy |), male patients with at least 2 drug administrations
(|Uν≥2,M,[y1,y2]|), male patients with at least one co-administration (|UΨ,M,[y1,y2]|), and male patients with at least one known
DDI co-administration (|UΦ,M,[y1,y2]|). Per age range women risk for both co-administration (RCM,[y1,y2]) and known DDI
co-administration (RIM,[y1,y2]) are listed in columns 6 and 7, respectively.
[y1, y2] |UF,[y1,y2]| |Uν≥2,F,[y1,y2]| |UΨ,F,[y1,y2]| |UΦ,F,[y1,y2]| RCF,[y1,y2] RIF,[y1,y2]
00-04 4,409 3,531 3,337 12 0.9451 0.0036
05-09 3,071 2,272 2,123 4 0.9344 0.0019
10-14 2,699 1,868 1,731 11 0.9267 0.0064
15-19 4,787 3,704 3,458 106 0.9336 0.0307
20-24 6,178 4,799 4,496 161 0.9369 0.0358
25-29 5,659 4,415 4,127 202 0.9348 0.0489
30-34 5,408 4,146 3,886 357 0.9373 0.0919
35-39 5,416 4,208 3,942 497 0.9368 0.1261
40-44 5,680 4,484 4,221 744 0.9413 0.1763
45-49 6,140 4,996 4,718 1,009 0.9444 0.2139
50-54 6,508 5,398 5,152 1,343 0.9544 0.2607
55-59 5,598 4,733 4,557 1,350 0.9628 0.2962
60-64 4,922 4,318 4,179 1,380 0.9678 0.3302
65-69 3,790 3,375 3,296 1,149 0.9766 0.3486
70-74 2,683 2,422 2,382 884 0.9835 0.3711
75-79 2,095 1,880 1,841 713 0.9793 0.3873
80-84 1,411 1,260 1,237 452 0.9817 0.3654
85-89 813 717 703 251 0.9805 0.3570
90+ 423 363 352 109 0.9697 0.3097
Supplementary Table 25: Absolute number of female patients and risk measures per age range ([y1, y2], 1st column).
Columns 2 through 5 lists, per age range, absolute numbers of: female patients (|Uy |), female patients with at least 2 drug
administrations (|Uν≥2,F,[y1,y2]|), female patients with at least one co-administration (|UΨ,F,[y1,y2]|), and female patients with
at least one known DDI co-administration (|UΦ,F,[y1,y2]|). Per age range women risk for both co-administration (RCF,[y1,y2])
and known DDI co-administration (RIF,[y1,y2]) are listed in columns 6 and 7, respectively.
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5.4 Risk Ratios per number of drug
# of drugs ν |Uν | |UΨ,ν | |UΦ,ν | RRCν RRIν
1 27,911 - - - -
2 25,032 20,517 283 1.0 1.0
3 19,163 18,468 677 1.1758 3.1249
4 14,305 14,185 929 1.2098 5.7443
5 11,026 11,010 1,208 1.2183 9.6908
6 8,587 8,583 1,425 1.2195 14.6785
7 6,438 6,438 1,512 1.2201 20.7735
8 4,970 4,970 1,477 1.2201 26.2865
9 3,877 3,877 1,417 1.2201 32.3283
10 2,932 2,932 1,335 1.2201 40.2742
11 2,264 2,264 1,089 1.2201 42.5462
12 1,691 1,691 936 1.2201 48.9600
13 1,214 1,214 754 1.2201 54.9366
14 937 937 641 1.2201 60.5101
15 618 618 413 1.2201 59.1113
16 482 482 368 1.2201 67.5320
17 366 366 285 1.2201 68.8768
18 268 268 218 1.2201 71.9500
19 177 177 142 1.2201 70.9617
20 131 131 105 1.2201 70.8969
>20 333 333 313 1.2201 83.1398
Supplementary Table 26: Absolute number of patients, join probabilities and relative risk per number of distinct drugs
dispensed, νu (1st column). By definition, patients who had only one distinct drug dispensed could not have had any co-
administration or interaction. Columns 2 through 4 lists, per distinct drugs dispensed, absolute numbers of: patients (|Uν |),
patients with at least one co-administration (|UΨ,ν |), and patients with at least one known DDI co-administration (|UΦ,ν |).
Per number of distinct drugs dispensed relative risks for both co-administration (RRCν) and known DDI co-administration
(RRIν) are listed in columns 5 and 6, respectively.
Supplementary Note 6 DDI Networks
For all pair of drugs known to interact we built two different networks, which are weighted versions of ∆.
In these networks weights are defined by either τΦi,j or |UΦi,j |. In this section we show alternatives plotting
schemes, additional subgraphs, and tables containing values used for plotting or inference. We also show a
Principal Component Analysis and two clustering methods performed on the networks.
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Supplementary Figure 7: Left. Node degree, deg(i), and node degree strength, degstr(i) =
∑
j τ
Φ
i,j , of weighted version of
network ∆ where weights are defined by τΦi,j . Right. Edge distribution of weighted version of network ∆, where weights are
defined by either τΦi,j or |UΦi,j |.
26
Ca
rd
iov
as
cu
lar
 ag
en
ts
CN
S 
ag
en
ts
Ho
rm
on
es
An
ti-
in
fe
ct
ive
s
Ps
yc
ho
th
er
ap
eu
tic
 ag
en
ts
Me
ta
bo
lic
 ag
en
ts
Re
sp
ira
to
ry
 ag
en
ts
Ga
st
ro
in
te
st
in
al 
ag
en
ts
Nu
tri
tio
na
l P
ro
du
ct
s
To
pi
ca
l A
ge
nt
s
Co
ag
ul
at
ion
 m
od
i
er
s
24
%
0.
03
%
No
de
s
Ed
ge
s
12345
12345
15,0
78
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne
Am
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le
M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
ilA
te
no
lol
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e
No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne
Am
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le
M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
ilA
te
no
lol
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e
No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne
Am
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le
M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
ilA
te
no
lol
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e
No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne
Am
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le
M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
ilA
te
no
lol
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e
No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne
Am
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le
M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
ilA
te
no
lol
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e
No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
S
u
p
p
le
m
en
ta
ry
F
ig
u
re
8:
A
w
ei
gh
te
d
ve
rs
io
n
of
ne
tw
or
k
∆
w
he
re
w
ei
gh
ts
ar
e
de
fin
ed
by
|U
Φ i,
j
|.
T
op
le
ft
.
Fe
m
al
e
D
D
I
ne
tw
or
k.
T
op
ri
gh
t.
M
al
e
D
D
I
ne
tw
or
k.
B
ot
to
m
le
ft
.
M
aj
or
D
D
I
ne
tw
or
k.
B
ot
to
m
ce
nt
er
.
M
od
er
at
e
D
D
I
ne
tw
or
k.
B
ot
to
m
ri
gh
t.
M
in
or
D
D
I
ne
tw
or
k.
N
od
es
de
no
te
dr
ug
s
i
in
vo
lv
ed
in
at
le
as
t
on
e
co
-a
dm
in
is
tr
at
io
n
kn
ow
n
to
be
a
D
D
I.
N
od
e
co
lo
r
re
pr
es
en
ts
th
e
hi
gh
es
t
le
ve
l
of
pr
im
ar
y
ac
ti
on
cl
as
s,
as
re
tr
ie
ve
d
fr
om
D
ru
gs
.c
om
(s
ee
le
ge
nd
)
N
od
e
si
ze
re
pr
es
en
ts
th
e
pr
ob
ab
ili
ty
of
in
te
ra
ct
io
n,
P
I
(i
),
as
de
fin
ed
in
m
ai
n
te
xt
.
E
d
ge
s
w
ei
gh
ts
ar
e
th
e
va
lu
e
of
|U
Φ i,
j
|,
th
e
nu
m
be
r
of
pa
ti
en
ts
aff
ec
te
d
by
th
e
D
D
I.
E
d
ge
co
lo
rs
de
no
te
R
R
I
g i,
j
,
w
he
re
g
∈
{M
,F
},
to
id
en
ti
fy
D
D
I
ed
ge
s
th
at
ar
e
hi
gh
er
ri
sk
fo
r
fe
m
al
es
(b
lu
e)
or
m
al
es
(r
ed
).
C
ol
or
in
te
ns
it
y
fo
r
R
R
I
g i,
j
va
ri
es
in
[1
,5
];
th
at
is
,
va
lu
es
ar
e
cl
ip
pe
d
at
5.
27
Ca
rd
iov
as
cu
lar
 ag
en
ts
CN
S 
ag
en
ts
Ho
rm
on
es
An
ti-
in
fe
ct
ive
s
Ps
yc
ho
th
er
ap
eu
tic
 ag
en
ts
Me
ta
bo
lic
 ag
en
ts
Re
sp
ira
to
ry
 ag
en
ts
Ga
st
ro
in
te
st
in
al 
ag
en
ts
Nu
tri
tio
na
l P
ro
du
ct
s
To
pi
ca
l A
ge
nt
s
Co
ag
ul
at
ion
 m
od
i
er
s
24
%
0.
03
%
No
de
s
Ed
ge
s
12345
12345
<0
.0
1
0.
70
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine
Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne A
m
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
il
At
en
olo
l
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine
Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne A
m
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
il
At
en
olo
l
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine
Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne A
m
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
il
At
en
olo
l
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine
Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne A
m
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
il
At
en
olo
l
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
Fe
no
te
ro
l
Ve
ra
pa
m
il
Fo
lic
 ac
id
Am
ox
ici
llin
Lo
sa
rta
n
Az
ith
ro
m
yc
in
Et
hin
yl 
Es
tra
di
ol
Cl
on
az
ep
am
Am
itr
ipt
yli
ne
Al
en
dr
on
at
e
Es
tro
ge
ns
 C
on
j.
Bi
pe
rid
en
M
et
oc
lop
ra
m
id
e
Iro
n (
II)
 S
ulf
at
e
Ca
rb
am
az
ep
ine
M
et
ro
nid
az
ole
Di
az
ep
am
Am
lod
ip
ine
W
ar
fa
rin
Ha
lop
er
id
ol
Ca
pt
op
ril
Le
vo
do
pa
Es
tra
di
ol
Pr
ed
nis
olo
ne
Lit
hiu
m
Tr
im
et
ho
pr
im
Hy
dr
oc
hlo
ro
th
iaz
id
e
M
ap
ro
til
ine
Ti
m
olo
l
No
r
ox
ac
in
Ph
en
yt
oin
Gl
yb
ur
id
e
Su
lfa
di
az
ine
Ep
ine
ph
rin
e
Ca
rv
ed
ilo
l
De
xa
m
et
ha
so
ne
To
br
am
yc
in
No
rtr
ipt
yli
ne
Ph
en
ob
ar
bi
ta
l
Sp
iro
no
lac
to
ne A
m
iod
ar
on
e
Ib
up
ro
fe
n
M
et
hy
ld
op
a
Cl
av
ula
na
te
AS
A
Si
m
va
st
at
in
Om
ep
ra
zo
le M
ed
ro
xy
pr
og
es
. A
c.
En
ala
pr
il
At
en
olo
l
Pr
ed
nis
on
e
Do
xy
cy
cli
ne
Flu
ox
et
ine
Di
clo
fe
na
c
Ac
et
am
ino
ph
en
Di
go
xin
Flu
co
na
zo
le
Hy
dr
oc
or
tis
on
e
Ge
nt
am
ici
n
Im
ip
ra
m
ine
Fu
ro
se
m
id
e
Ch
lor
pr
om
az
ine
Am
ino
ph
yll
ine
Ci
pr
o
ox
ac
in
Le
vo
th
yr
ox
ine
M
et
hy
lp
he
nid
at
e No
re
th
ist
er
on
e
Sa
lb
ut
am
ol
Gl
icl
az
id
e
Er
yt
hr
om
yc
in
Le
vo
no
rg
es
tre
l
Pr
op
ra
no
lol
Di
lti
az
em
Al
lop
ur
ino
l
Pr
op
ylt
hio
ur
ac
il
S
u
p
p
le
m
en
ta
ry
F
ig
u
re
9:
A
w
ei
gh
te
d
ve
rs
io
n
of
ne
tw
or
k
∆
w
he
re
w
ei
gh
ts
ar
e
de
fin
ed
by
τ
Φ i,
j
.
T
op
le
ft
.
Fe
m
al
e
D
D
I
ne
tw
or
k.
T
op
ri
gh
t.
M
al
e
D
D
I
ne
tw
or
k.
B
ot
to
m
le
ft
.
M
aj
or
D
D
I
ne
tw
or
k.
B
ot
to
m
ce
nt
er
.
M
od
er
at
e
D
D
I
ne
tw
or
k.
B
ot
to
m
ri
gh
t.
M
in
or
D
D
I
ne
tw
or
k.
N
od
es
de
no
te
dr
ug
s
i
in
vo
lv
ed
in
at
le
as
t
on
e
co
-a
dm
in
is
tr
at
io
n
kn
ow
n
to
be
a
D
D
I.
N
od
e
co
lo
r
re
pr
es
en
ts
th
e
hi
gh
es
t
le
ve
l
of
pr
im
ar
y
ac
ti
on
cl
as
s,
as
re
tr
ie
ve
d
fr
om
D
ru
gs
.c
om
(s
ee
le
ge
nd
)
N
od
e
si
ze
re
pr
es
en
ts
th
e
pr
ob
ab
ili
ty
of
in
te
ra
ct
io
n,
P
I
(i
),
as
de
fin
ed
in
m
ai
n
te
xt
.
E
d
ge
s
w
ei
gh
ts
ar
e
th
e
va
lu
e
of
τ
Φ i,
j
,
ob
ta
in
ed
fr
om
E
qu
at
io
n
4,
a
no
rm
al
iz
ed
m
ea
su
re
of
th
e
de
gr
ee
to
w
hi
ch
a
sp
ec
ifi
c
D
D
I
is
co
-p
re
sc
ri
be
d.
E
d
ge
co
lo
rs
de
no
te
R
R
I
g i,
j
,
w
he
re
g
∈
{M
,F
},
to
id
en
ti
fy
D
D
I
ed
ge
s
th
at
ar
e
hi
gh
er
ri
sk
fo
r
fe
m
al
es
(b
lu
e)
or
m
al
es
(r
ed
).
C
ol
or
in
te
ns
it
y
fo
r
R
R
I
g i,
j
va
ri
es
in
[1
,5
];
th
at
is
,
va
lu
es
ar
e
cl
ip
pe
d
at
5.
28
1 2 3 4 5 6 7 8 9
Components
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
%
95% with 26
singular vectors
Explained variance ratio
0 10 20
Component 1
5
0
5
10
15
Co
m
po
ne
nt
 2
Components 1 and 2
Phenytoin
Phenobarbital
Carbamazepine
Warfarin
Propranolol
Atenolol
5 0 5 10 15
Component 2
0
5
10
15
Co
m
po
ne
nt
 3
Components 2 and 3
Propranolol
Carbamazepine
Atenolol
Digoxin
Warfarin
5 0 5 10 15
Component 3
5
0
5
10
Co
m
po
ne
nt
 4
Components 3 and 4
Warfarin
Propranolol
Digoxin
ASA
Lithium
Fluoxetine
Carbamazepine
5 0 5 10 15
Component 4
5
0
5
10
Co
m
po
ne
nt
 5
Components 4 and 5
Carbamazepine
Fluoxetine
Lithium
Warfarin
Digoxin
ASA
5 0 5 10 15
Component 5
5
0
5
10
Co
m
po
ne
nt
 6
Components 5 and 6
Digoxin
Lithium
Glyburide
Diltiazem
Warfarin
5 0 5 10
Component 6
5
0
5
Co
m
po
ne
nt
 7
Components 6 and 7
Lithium
Methyldopa
Gliclazide
Glyburide
Diltiazem
Digoxin
5 0 5
Component 7
5
0
5
Co
m
po
ne
nt
 8
Components 7 and 8
Digoxin
Furosemide
Ethinyl Estradiol
Doxycycline
ASA
Lithium
Gliclazide
Methyldopa
Glyburide
5 0 5
Component 8
0
5
Co
m
po
ne
nt
 9
Components 8 and 9
Doxycycline
Ethinyl Estradiol
Haloperidol
Diltiazem
Imipramine
Nortriptyline
Amitriptyline
ASA
Furosemide
Supplementary Figure 10: Principal Component Analysis (PCA) of network where weights are defined by τΦi,j . Top Left.
Explained variance ratio for the first 9 principal components. Additional plots. Projection of network nodes (drugs) given
the respective principal component. Nodes with loading ≥ 2 s.d. in either component are annotated.
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Supplementary Figure 11: Principal Component Analysis (PCA) of network where weights are defined by |UΦi,j |. Top Left.
Explained variance ratio for the first 9 principal components. Additional plots. Projection of network nodes (drugs) given
the respective principal component. Nodes with loading ≥ 2 s.d. in either component are annotated.
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i deg(i) degstr(i) betweenness(i) PI(i) class
Phenytoin 24 6.51 0.30 0.20 CNS agents
Phenobarbital 15 2.17 0.28 0.05 CNS agents
Ethinyl Estradiol 9 1.78 0.03 0.04 Hormones
Doxycycline 8 1.39 0.02 0.04 Anti-infectives
Prednisone 7 0.96 0.02 0.03 Hormones
Prednisolone 6 0.54 0.03 0.00 Hormones
Diazepam 5 1.12 0.05 0.09 CNS agents
Erythromycin 5 0.20 0.18 0.01 Anti-infectives
Estradiol 4 0.57 0.00 0.01 Hormones
Estrogens Conj. 4 0.58 0.00 0.01 Hormones
Norethisterone 3 0.73 0.00 0.00 Hormones
Levonorgestrel 3 0.79 0.00 0.00 Hormones
Medroxyproges. Ac. 3 1.06 0.00 0.00 Hormones
Omeprazole 3 0.85 0.00 0.05 Gastrointestinal agents
Folic acid 2 0.50 0.00 0.00 Nutritional Products
Clonazepam 2 0.42 0.00 0.09 CNS agents
Amoxicillin 2 0.30 0.00 0.00 Anti-infectives
Clavulanate 2 0.23 0.00 0.00 Anti-infectives
Sulfadiazine 1 0.51 0.00 0.01 Anti-infectives
Trimethoprim 1 0.16 0.00 0.00 Anti-infectives
Carbamazepine 18 4.84 0.20 0.18 CNS agents
Fluoxetine 10 3.41 0.02 0.06 Psychotherapeutic agents
Haloperidol 6 2.32 0.03 0.20 Psychotherapeutic agents
Lithium 9 2.05 0.13 0.17 Psychotherapeutic agents
Fluconazole 10 1.74 0.09 0.11 Anti-infectives
Salbutamol 7 1.53 0.00 0.03 Respiratory agents
Amitriptyline 5 1.47 0.00 0.08 Psychotherapeutic agents
Imipramine 5 1.31 0.01 0.07 Psychotherapeutic agents
Nortriptyline 5 1.30 0.00 0.09 Psychotherapeutic agents
Fenoterol 8 0.81 0.13 0.01 Respiratory agents
Biperiden 1 0.70 0.00 0.13 CNS agents
Methylphenidate 1 0.24 0.00 0.02 CNS agents
Losartan 1 0.21 0.00 0.00 Cardiovascular agents
Captopril 1 0.18 0.00 0.00 Cardiovascular agents
Metronidazole 3 0.17 0.16 0.00 Anti-infectives
Enalapril 1 0.16 0.00 0.00 Cardiovascular agents
Methyldopa 7 2.30 0.01 0.06 Cardiovascular agents
Iron (II) Sulfate 5 1.12 0.02 0.04 Nutritional Products
Levodopa 3 0.97 0.03 0.01 CNS agents
Ciprofloxacin 4 0.35 0.21 0.01 Anti-infectives
Norfloxacin 2 0.29 0.00 0.01 Anti-infectives
Metoclopramide 1 0.11 0.00 0.00 Gastrointestinal agents
Supplementary Table 27: Louvain modules of weighted version of network ∆ where weights are defined by τΦi,j . Each
Louvain module is shown separated by a horizontal line. Drugs nodes (i; 1nd column) and their respective degree, degree
strength, and betweenness centrality measure, shown in columns 2, 3, and 4, respectively Column 5 shows the drug probability
of interaction, PI(i). Drug class is shown in column 6. Continues on Supplementary Table 28.
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i deg(i) degstr(i) betweenness(i) PI(i) class
Digoxin 9 3.70 0.03 0.24 Cardiovascular agents
Warfarin 14 3.31 0.17 0.13 Coagulation modifiers
Diltiazem 6 2.66 0.03 0.13 Cardiovascular agents
Amiodarone 3 1.40 0.00 0.02 Cardiovascular agents
Furosemide 5 1.31 0.05 0.04 Cardiovascular agents
Levothyroxine 3 1.15 0.00 0.01 Hormones
Simvastatin 4 1.07 0.00 0.02 Metabolic agents
Propylthiouracil 2 0.87 0.00 0.01 Hormones
Hydrochlorothiazide 2 0.69 0.00 0.00 Cardiovascular agents
Spironolactone 1 0.55 0.00 0.02 Cardiovascular agents
Allopurinol 1 0.46 0.00 0.01 Metabolic agents
Amlodipine 1 0.34 0.00 0.00 Cardiovascular agents
Acetaminophen 1 0.22 0.00 0.00 CNS agents
Gentamicin 1 0.12 0.00 0.02 Anti-infectives
Diclofenac 2 0.09 0.03 0.01 CNS agents
Tobramycin 1 0.08 0.00 0.00 Topical Agents
Azithromycin 1 0.07 0.00 0.00 Anti-infectives
Alendronate 1 0.04 0.00 0.01 Metabolic agents
Aminophylline 10 1.93 0.23 0.01 Respiratory agents
Hydrocortisone 3 0.06 0.20 0.01 Hormones
Timolol 7 1.11 0.16 0.06 Cardiovascular agents
Ibuprofen 7 1.28 0.06 0.05 CNS agents
Atenolol 8 2.22 0.05 0.06 Cardiovascular agents
Propranolol 14 4.81 0.06 0.10 Cardiovascular agents
ASA 7 1.57 0.01 0.07 CNS agents
Verapamil 4 1.11 0.01 0.04 Cardiovascular agents
Glyburide 5 2.29 0.00 0.12 Metabolic agents
Carvedilol 6 1.70 0.00 0.07 Cardiovascular agents
Gliclazide 5 1.64 0.00 0.12 Metabolic agents
Chlorpromazine 1 0.33 0.00 0.00 CNS agents
Dexamethasone 3 0.24 0.00 0.03 Hormones
Maprotiline 1 0.23 0.00 0.01 Psychotherapeutic agents
Epinephrine 1 0.0 0.0 0.02 Respiratory agents
Supplementary Table 28: Continuation. See Supplementary Table 27 for column description.
32
i deg(i) degstr(i) betweenness(i) PI(i) class
Phenytoin 24 6.51 0.30 0.20 CNS agents
Phenobarbital 15 2.17 0.28 0.05 CNS agents
Ethinyl Estradiol 9 1.78 0.03 0.04 Hormones
Doxycycline 8 1.39 0.02 0.04 Anti-infectives
Prednisone 7 0.96 0.02 0.03 Hormones
Prednisolone 6 0.54 0.03 0.00 Hormones
Estradiol 4 0.57 0.00 0.01 Hormones
Estrogens Conj. 4 0.58 0.00 0.01 Hormones
Dexamethasone 3 0.24 0.00 0.03 Hormones
Norethisterone 3 0.73 0.00 0.00 Hormones
Hydrocortisone 3 0.06 0.20 0.01 Hormones
Levonorgestrel 3 0.79 0.00 0.00 Hormones
Medroxyproges. Ac. 3 1.06 0.00 0.00 Hormones
Folic acid 2 0.50 0.00 0.00 Nutritional Products
Amoxicillin 2 0.30 0.00 0.00 Anti-infectives
Clavulanate 2 0.23 0.00 0.00 Anti-infectives
Sulfadiazine 1 0.51 0.00 0.01 Anti-infectives
Trimethoprim 1 0.16 0.00 0.00 Anti-infectives
Propranolol 14 4.81 0.06 0.10 Cardiovascular agents
Methyldopa 7 2.30 0.01 0.06 Cardiovascular agents
Glyburide 5 2.29 0.00 0.12 Metabolic agents
Atenolol 8 2.22 0.05 0.06 Cardiovascular agents
Aminophylline 10 1.93 0.23 0.01 Respiratory agents
Carvedilol 6 1.70 0.00 0.07 Cardiovascular agents
Gliclazide 5 1.64 0.00 0.12 Metabolic agents
ASA 7 1.57 0.01 0.07 CNS agents
Salbutamol 7 1.53 0.00 0.03 Respiratory agents
Ibuprofen 7 1.28 0.06 0.05 CNS agents
Iron (II) Sulfate 5 1.12 0.02 0.04 Nutritional Products
Timolol 7 1.11 0.16 0.06 Cardiovascular agents
Verapamil 4 1.11 0.01 0.04 Cardiovascular agents
Levodopa 3 0.97 0.03 0.01 CNS agents
Ciprofloxacin 4 0.35 0.21 0.01 Anti-infectives
Chlorpromazine 1 0.33 0.00 0.00 CNS agents
Norfloxacin 2 0.29 0.00 0.01 Anti-infectives
Maprotiline 1 0.23 0.00 0.01 Psychotherapeutic agents
Metoclopramide 1 0.11 0.00 0.00 Gastrointestinal agents
Supplementary Table 29: InfoMap modules of weighted version of network ∆ where weights are defined by τΦi,j . Each
InfoMap module is shown separated by a horizontal line. Drugs nodes (i; 1nd column) and their respective degree, total degree
strength (, and betweenness centrality measure, shown in columns 2, 3, and 4, respectively Column 5 shows the drug probability
of interaction, PI(i). Drug class is shown in column 6. Continues on Supplementary Table 30.
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i deg(i) degstr(i) betweenness(i) PI(i) class
Carbamazepine 18 4.84 0.20 0.18 CNS agents
Fluoxetine 10 3.41 0.02 0.06 Psychotherapeutic agents
Fluconazole 10 1.74 0.09 0.11 Anti-infectives
Amitriptyline 5 1.47 0.00 0.08 Psychotherapeutic agents
Imipramine 5 1.31 0.01 0.07 Psychotherapeutic agents
Nortriptyline 5 1.30 0.00 0.09 Psychotherapeutic agents
Fenoterol 8 0.81 0.13 0.01 Respiratory agents
Methylphenidate 1 0.24 0.00 0.02 CNS agents
Digoxin 9 3.70 0.03 0.24 Cardiovascular agents
Warfarin 14 3.31 0.17 0.13 Coagulation modifiers
Furosemide 5 1.31 0.05 0.04 Cardiovascular agents
Levothyroxine 3 1.15 0.00 0.01 Hormones
Propylthiouracil 2 0.87 0.00 0.01 Hormones
Hydrochlorothiazide 2 0.69 0.00 0.00 Cardiovascular agents
Spironolactone 1 0.55 0.00 0.02 Cardiovascular agents
Allopurinol 1 0.46 0.00 0.01 Metabolic agents
Acetaminophen 1 0.22 0.00 0.00 CNS agents
Gentamicin 1 0.12 0.00 0.02 Anti-infectives
Tobramycin 1 0.08 0.00 0.00 Topical Agents
Azithromycin 1 0.07 0.00 0.00 Anti-infectives
Haloperidol 6 2.32 0.03 0.20 Psychotherapeutic agents
Lithium 9 2.05 0.13 0.17 Psychotherapeutic agents
Biperiden 1 0.70 0.00 0.13 CNS agents
Losartan 1 0.21 0.00 0.00 Cardiovascular agents
Captopril 1 0.18 0.00 0.00 Cardiovascular agents
Metronidazole 3 0.17 0.16 0.00 Anti-infectives
Enalapril 1 0.16 0.00 0.00 Cardiovascular agents
Diltiazem 6 2.66 0.03 0.13 Cardiovascular agents
Amiodarone 3 1.40 0.00 0.02 Cardiovascular agents
Simvastatin 4 1.07 0.00 0.02 Metabolic agents
Amlodipine 1 0.34 0.00 0.00 Cardiovascular agents
Diazepam 5 1.12 0.05 0.09 CNS agents
Omeprazole 3 0.85 0.00 0.05 Gastrointestinal agents
Clonazepam 2 0.42 0.00 0.09 CNS agents
Erythromycin 5 0.20 0.18 0.01 Anti-infectives
Diclofenac 2 0.09 0.03 0.01 CNS agents
Alendronate 1 0.04 0.00 0.01 Metabolic agents
Epinephrine 1 0.0 0.0 0.02 Respiratory agents
Supplementary Table 30: Continuation. See Supplementary Table 29 for column description.
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Supplementary Note 7 Null Model for RIy
To test if sheer combinatorics explains the increased risk of DDI in older age, we compared the observed
risk of interactions RIy with a random null model, Hrnd0 . We separated all patients u in our dataset per
age range y. From these subset of patients U [y1,y2] we also separated which drugs d were prescribed in their
age range as D[y1−y2]. For clarity, we will refer to all measures previously reported with an added star (?)
in the notation to indicate that these values are calculated for the null model (e.g., RIy? is the null model
value of the risk of interaction per age range, RIy).
The null model is then computed by proportionally sampling patients for each age range, u ∈ U [y1−y2].
For each drawn patient u we sampled |Du| drugs available to patients in the patient’s age range D[y1,y2], and
then randomly drew Ψu co-administrations from the patient’s possible pairwise combinations
(|Du|
2
)
of drugs,
thus yielding random drug pairs ψu?i,j that matched the observed number of co-administrations, Ψu ≡ Ψu?.
To decide if a co-administration is an interaction in the null model, we compare the randomly drawn pair of
drugs against DrugBank to decide if ϕu?i,j is an interaction or not.
This null model allow us to measure what is the expected number of interactions given the increase of
co-administrations observed with age, assuming drugs are prescribed completely at random. In other words,
it measures the risk of DDI if only age, and the drugs available to patients in these ages, were given to them
at random with the same number of co-administrations.
To compute confidence intervals for the number of patients in the null model, we proportionally sampled
the same number of patients observed in each age range, 100 times. Confidence intervals can be seen as
background fills in Figures 2 and 4. To measure the significance of our null models, Supplementary Table
31 shows the chi-square tests against the expected number of patients in each age bin, |U [y1,y2]|, from our
data. The null model rejects the hypothesis it was sampled from the same distribution as our data. This
means the observed increase in DDI with age, seen in our data, cannot be explained alone by the increased
combinatorics of drug co-administrations alone.
model chi-square p-value
1 Hrnd0 22378.5912 0.0
Supplementary Table 31: Chi-square statistic when the number of patients in the null model, |Uy?|, is compared to the
observed values, |Uy |.
Supplementary Note 8 Interactions per Neighborhood
Supplementary Figure 12 shows the number of drugs dispensed for each neighborhood N , colored by the
average income of its residents, R$ (Reais). Naturally, the larger the neighborhood population (ΩN ), the
more drugs are dispensed (αN ), leading to a fairly clear linear relationship (R2 = 623, p = 0.0). Some
observed exceptions above and below the regression line are noteworthy, though. Three neighborhoods—
Itoupavazinha, Velha Central and Água Verde—display dispensation levels below what is expected for their
population (circled in Cyan in Supplementary Figure 12-left). On the other hand, two neighborhoods that are
also not among the wealthiest—Fortaleza and Tribess—are well above the expected drug dispensation (circled
in magenta). Looking at these specific neighborhoods will require further work to be better understood. In
any case, their identification highlights the benefits of analyzing EHR and a data science approach to support
responsive public health policy.
For a visual inspection of how both official survey numbers and those analyzed in the main manuscript
related geographically in the city of Blumenau, we have mapped neighborhoods to results in Supplementary
Figures 13 and 14. The first figure denotes neighborhoods mapped to official numbers from IBGE[7], such
as population, gender rate and income distribution. The second figure denotes dispensed drug intervals,
distinct drugs, co-administrations and interactions mapped to each neighborhood.
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Supplementary Figure 12: Left. Number of drugs intervals dispensed αN against population ΩN in each neighborhood
N . Right. Number of drug intervals dispensed (αN ) versus number of interactions (ΦN ), per neighborhood (N), normalized
by population (ΩN ). Color denotes the average per capita income of neighborhood, in Brazilian Reais (R$). Regression line
shown in green. Patients who reported living in neighborhood Other were discarded from computation. Cartographic shapes
from IBGE [7].
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Supplementary Figure 13: Data from IBGE [7] mapped to geographical neighbourhoods in the city of Blumenau. Left. Pop-
ulation probability, P (ΩN ). Center. Gender rate, ΩN,g=F /ΩN,g=M . Right. Average income in Brazilian Reais (R$/month).
See Supplementary Note 9 for details on income. Cartographic shapes from IBGE [7].
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Supplementary Figure 14: Results from Pronto data mapped to geographical neighbourhoods in the city of Blumenau.
Top left. Number of drug interval dispensed per capita, αN/ΩN . Top right. Distinct drugs dispensed per capita, νN/ΩN .
Bottom left. Number of co-adminstrations per capita, ΨN/ΩN . Bottom right. Number of interactions per capita, ΦN/ΩN .
Cartographic shapes from IBGE [7].
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Supplementary Note 9 Projected Cost of DDI in hospitalizations
Estimating the financial burden of DDI prescribed in primary and secondary care is difficult, since outcomes
vary by a large margin and only few result in short-term symptoms requiring hospitalization. Measuring hos-
pitalizations due to DDI are also strenuous, since underestimation of true risk can be masked in practitioners
and pharmacists failing to recognize adverse patient outcomes caused by DDI as such. However, drug- and
cohort-focused studies have shown that the number of DDI is associated with a significantly increased risk
of hospitalization [21, 22]. A review paper in 2007 [23] estimated that DDI were held responsible for 0.054%
of emergency room (ER) visits, 0.57% of hospital admissions (4.8% in the elderly population) and 0.12% of
re-hospitalizations. The most common outcomes were gastrointestinal bleeding (32.8%), hypertension/hy-
potension (18%) and cardiac rhythm disturbances (18%).
In this section a study of the financial burden of possible DDI-related hospitalizations is presented. It
considers various rates of hospitalization expected for major DDI co-administrations, and is based on a
cost estimate of ADR hospitalizations in Canada [24], and average hospitalization costs for Brazil at city,
state and national levels. As average hospitalization costs were not found for the United States, results in
Canadian dollars were also converted to US dollars. Our estimation then relies on guessing what proportion
of patients with major DDI co-administrations are likely to have an ADR requiring hospitalization.
To compute costs we gathered number of public health care hospitalizations and average costs for each
level (see Supplementary Table 32) from the national Hospitalization Information System (Sistema de Infor-
mações Hospitalares do SUS ; SIH/SUS), a data source managed by the Informatics Department under the
Executive Secretary of Brazil’s Ministry of Health [25].
As reported, the number of patients prescribed a major DDI in Blumenau (city level) was |UΦ,s=major| =
5, 224. For state and national levels, we estimated this number from the percentage of hospitalizations it
represents at city level, a reasonable assumption due the lack of data that generalizes medical practice in
Blumenau for the state and country. For example, say 261 (or 5%) Pronto patients prescribed a major
DDI had to be hospitalized. In hospitalization terms, that accounts for 1.06% of all hospitalizations in
the same period. At the state and national level, the same 1.06% accounts for 5,376 and 142,564 patients,
respectively. Costs are then estimated by multiplying the number of patients assumed hospitalized by the
average hospitalization cost in each level.
Wu et al. [24] argued in 2007 that the average cost of ADR-related hospitalization for all adults over 65 in
the province of Ontario (pop. 12M in 2006; 13.6M in 2014) was C$ 7,528 (C$ 8,443.14 or $7,380.78 in 2014
when adjusted for inflation and exchange rate) for a total annual cost of C$ 13.6 million (C$ 15.2M or $13.3M
after adjusting), or estimated C$ 35.7 million (C$ 40M or $35M after adjusting) in Canada. In an attempt
to compare results, we also multiplied the number of patients assumed to have been hospitalized to their
average cost of ADR-relation hospitalization (see columns 6 and 7 of Supplementary Table 33). Moreover,
Blumenau Santa Catarina Brazil Ontario
city state national province
Population 338,876 6,819,190 204,450,649 13,680,425
Hospitalization
Elective 9,761 146,395 3,391,088 -
Urgent 24,592 (5,808) 507,189 (110,748) 13,440,043 (2,711,527) -
Work Accident 87 2,106 64,485 -
External Causes 786 902 110,922 -
Total 35,226 656,592 17,006,538 -
Avg. Cost
Elective R$ 3,764.62 R$ 1,533.10 R$ 1,583.45 -
Urgent R$ 2,606.03 R$ 1,379.13 R$ 1,083.23 C$ 8,443.14
Work Accident R$ 1,663.27 R$ 2,595.45 R$ 1,541.38 -
External Causes R$ 2,321.31 R$ 2,203.50 R$ 1,256.36 -
Supplementary Table 32: Population, number of hospitalizations, and average cost per hospitalization in the analyzed
period shown for city, state and national levels. Population follows the official projections for 2015. Hospitalization numbers
and cost shown by type. Urgent hospitalization values in parenthesis shown for patients over 64 years old. Note Blumenau has
a much higher average cost per hospitalization than state and national levels. Brazil data from Hospitalization Information
System (Sistema de Informações Hospitalares do SUS; SIH/SUS) [25]. Ontario data from Wu et al. [24], adjusted for inflation.
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Supplementary Tables 33, 34 and 35 show the estimated costs at different percentages of hospitalizations at
city, state and national levels, respectively. Costs in Brazilian Reais (columns 4 and 5) are computed based
on the average cost of hospitalization in Brazil. Costs in C$ use Wu et al. [24] as reference (columns 6 and
7), and then converted to US$ with the average exchange rate between the two currencies for the whole
period of our data (columns 8 and 9). The average exchange rate in the period was C$1.00 Canadian dollar
equals to $0.8742 US dollar, and maximum and minimum rates were .9418 in January 4th 2014 and .7821 in
March 14th 2015, respectively.
Our cost analysis first considers two previous studies of the proportion of emergency room visits that are
due to DDI and ADR. Becker et al. [23] reported that 0.57% of all hospital admissions they observed were
due to DDI, which in our data would correspond to 140 patients, or ph = 2.68% of all patients dispensed
a major DDI (see Supplementary Table 33). Wu et al. [24], on the other hand, argued that 0.75% of all
hospitalizations of patients over 65 years of age were due to ADR (not only from DDI), which corresponds
in our data to 436 patients, or ph = 8.35% of all patients who were co-administered a major DDI. Both of
these conjectures are likely to err on the side of under-reporting emergency room admissions due to DDI
or ADR, since this a well-known problem in studies of this phenomenon [26–30]. Indeed, the proportion
of hospital admissions due to ADR has been reported in the literature to vary anywhere between 0.5% to
12% [28], with DDI reportedly being responsible for 15% [29] to 30% [31] of all ADR. These ranges, if
correct, put the proportion of hospital admissions due to DDI anywhere between 0.5%× 15% = 0.075% and
12%× 30% = 3.6%, which in our Blumenau data would mean between 18 and 885 emergency room patients,
or ph ∈ [0.35, 16.95]% of all patients dispensed a major DDI. These ranges could be higher, since even in
the more controlled hospital environment, the proportion of patients with ADR can be as high as 41% [32].
Therefore, in addition to the costs derived from the numbers provided by Becker et al. [23] and Wu et al.
[24], tables in this section also report cost estimates for various values of ph, so that readers can judge what
is an appropriate value to consider. Given the ranges just outlined, it is reasonable to assume, for instance,
that ph = 10% of all patients dispensed a major DDI will have to be hospitalized (522 patients).
The lowest estimate (ph = 2.68%, via Becker et al. [23]) leads to a cost of DDI-related hospitalization
in Blumenau of over $1M in the 18-month period, after adjusting for Canadian cost, inflation and exchange
rate to US dollar. The extrapolated costs to the state and the country are $21M and $565M, respectively
(see Supplementary Tables 34 and 35). The estimated costs obtained via Wu et al. [24] (ph = 8.35%) reach
$3.2M, $61M, and $1.5B, for the city, state and country levels respectively. Finally, if we assume ph = 10%,
the estimated costs reach $3.9M, $79M, and $2.1B, for the city, state and country levels respectively.
All estimations lead to very substantial costs for the various levels of government. To compare them to the
costs found for Canada [24], we computed per capita measures of the burden of DDI-related hospitalizations.
For instance, the lowest estimate ph = 2.68% leads to a per capita cost for Blumenau of $2.03, while
the inflation-adjusted cost for Ontario (Canada) is $0.97, suggesting that the financial burden of DDI is
more severe than previously thought—even when considering only the lowest estimate of the proportion of
hospitalizations that derive from co-administration of known major DDIs. For the state of Santa Catarina
and Brazil as a whole, these numbers are $2.09 and $1.84, respectively. If we consider the higher estimates
of ph = 8.35% or ph = 10%, the per capita cost for Blumenau is $6.33 and $7.58, respectively.
To put these numbers in context, Brazil’s minimum monthly wage was R$724 (R$9,412/year3) in 2014,
and workers in Blumenau received on average 2.9 wages a month [7]. This constitutes an average gross income
of R$2,099.60 a month (R$27,294.80/year). If we assume the same 140 patients were hospitalized due to
ADR caused by DDI, the direct cost of such hospitalizations is equal to 3,707 lost productive worker/days
(considering an 8 hour working day), with possible much higher indirect costs.
Some limitations should be noted. When comparing to Becker et al. [23], data from IBGE–Instituto
Brasileiro de Geografia e Estatística [7] includes patients over 64, while in their work the authors included
patients over 65 years old. Our analysis then possibly contains additional patients exactly age 65, although
we do not believe this affects the results presented given their large difference. In general, other studies [23]
divide hospital admissions only between two categories, emergency room (ER) visits and hospitalizations.
It is not possible to conclude whether electives or external causes are included in their hospitalization
numbers. SIH/SUS data are only available for patients that were hospitalized in the public system, meaning
3Brazilians receive a 13th salary in December. Thus, yearly gross income is calculated by a 13, and not by a 12, multiplier.
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Cost R$ Cost CA$ Cost US$
ph |UΦmajor| % of hosp. 18 months 12 months 18 months 12 months 18 months 12 months
100% 5,224 21.24% 13,613,909 9,075,940 44,106,963 29,404,642 38,557,213 25,704,809
50% 2,612 10.62% 6,806,955 4,537,970 22,053,482 14,702,321 19,278,606 12,852,404
30% 1,567 6.37% 4,083,652 2,722,434 13,230,400 8,820,267 11,565,688 7,710,458
25% 1,306 5.31% 3,403,477 2,268,985 11,026,741 7,351,161 9,639,303 6,426,202
20% 1,044 4.25% 2,720,697 1,813,798 8,814,638 5,876,425 7,705,538 5,137,025
10% 522 2.12% 1,360,349 906,899 4,407,319 2,938,213 3,852,769 2,568,513
5% 261 1.06% 680,174 453,450 2,203,660 1,469,106 1,926,384 1,284,256
2.68% 140 0.57% 364,844 243,230 1,182,040 788,026 1,033,310 688,873
8.35% 436 0.75% 1,136,230 757,487 3,681,209 2,454,139 3,218,022 2,145,348
Supplementary Table 33: Projected cost of DDI for the city of Blumenau in Reais (R$), Canadian Dollars (C$) and US
dollars (US$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on
different proportion of patients who had at least one major DDI and required hospitalization. Last row shows the projected
cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of Wu et al. [24].
Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization are considered, based on results of
Becker et al. [23]. In the 18 month period, Blumenau had a total of 24,592 public health care emergency hospitalizations, from
which 5,808 were of patients age over 64 years old. Average cost per hospitalization in the city is R$ 2,606.03. US$ costs were
calculated based on C$ exchange rate of .8742, the average rate in the study period.
Cost in R$ Cost in CA$ Cost in US$
ph |UΦmajor| % of hosp. 18 months 12 months 18 months 12 months 18 months 12 months
100% 107,726 21.24% 148,567,620 99,045,080 909,545,700 606,363,800 795,102,280 530,068,187
50% 53,863 10.62% 74,283,810 49,522,540 454,772,850 303,181,900 397,551,140 265,034,093
30% 32,307 6.37% 44,555,391 29,703,594 272,772,524 181,848,349 238,450,972 158,967,314
25% 26,931 5.31% 37,141,215 24,760,810 227,382,203 151,588,136 198,771,880 132,514,586
20% 21,555 4.25% 29,727,039 19,818,026 181,991,883 121,327,922 159,092,788 106,061,859
10% 10,752 2.12% 14,828,352 9,885,568 90,780,641 60,520,428 79,358,184 52,905,456
5% 5,376 1.06% 7,414,176 4,942,784 45,390,321 30,260,214 39,679,092 26,452,728
2.68% 2,890 0.57% 3,985,671 2,657,114 24,400,675 16,267,116 21,330,464 14,220,309
7.71% 8,306 0.75% 21,645,699 14,430,466 70,128,721 46,752,481 61,304,788 40,869,858
Supplementary Table 34: Projected cost of DDI for the state of Santa Catarina in Reais (R$), Canadian Dollars (C$) and
US dollars (US$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based
on different proportion of patients who had at least one major DDI and required hospitalization. Last row shows the projected
cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of Wu et al. [24].
Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization are considered, based on results of
Becker et al. [23]. In the 18 month period, Santa Catarina had a total of 507,189 public health care emergency hospitalizations.
Average cost per hospitalization in the state is R$ 1,379.13. US$ costs were calculated based on C$ exchange rate of .8742, the
average rate in the study period.
the cost of hospitalization was billed to the public system. Therefore, if a patient was hospitalized and
his/her private insurance covered the costs, the SIH/SUS would have no record of it. Furthermore, SIH/SUS
provides the number of hospitalizations broken down by type. These consist of “electives” (e.g., schedules
cesareans), “urgencies”, “work accidents”, and “other external causes” (codes V01 to Y98 of ICD-104; e.g., car
accident, poisoning, and drowning). To better approximate reality, we have calculated the cost of DDI-related
hospitalizations only using the number of urgent hospitalizations.
4http://www.datasus.gov.br/cid10/V2008/WebHelp/v01_y98.htm
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Cost in R$ Cost in CA$ Cost in US$
ph |UΦmajor| % of hosp. 18 months 12 months 18 months 12 months 18 months 12 months
100% 2,854,665 21.24% 3,092M 2,061M 24,102M 16,068M 21,070M 14,046M
50% 1,427,332 10.62% 1,546M 1,031M 12,051M 8,034M 10,535M 7,023M
30% 856,130 6.37% 927M 618M 7,228M 4,819M 6,319M 4,213M
25% 713,666 5.31% 773M 515M 6,026M 4,017M 5,267M 3,512M
20% 571,201 4.25% 619M 412M 4,823M 3,215M 4,216M 2,811M
10% 284,928 2.12% 309M 206M 2,406M 1,604M 2,103M 1,402M
5% 142,464 1.06% 154M 103M 1,203M 802M 1,051M 701M
2.68% 76,608 0.57% 83M 55M 647M 431M 565M 377M
7.12% 203,365 0.75% 530M 353M 1,717M 1,145M 1,501M 1,001M
Supplementary Table 35: Projected cost of DDI for Brazil in Reais (R$), Canadian Dollars (C$) and US dollars (US$) for
the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on different proportion
of patients who had at least one major DDI and required hospitalization. Last row shows the projected cost when only 0.75%
of all hospitalizations of patients over 64 years old are considered, based on results of Wu et al. [24]. Similarly, second-to-last
row shows projected cost when only 0.57% of all hospitalization are considered, based on results of Becker et al. [23]. In the 18
month period, Brazil had a total of 13,440,043 public health care emergency hospitalizations. Average cost per hospitalization
in the country is R$ 1,083.23. US$ costs were calculated based on C$ exchange rate of .8742, the average rate in the study
period.
Supplementary Note 10 Statistical modeling
Here we show the complete results from runs of simple regression (SR), polynomial regression (PR), ordinary
multiple regression (OMR) and linear mixed model (LMM) that were mentioned in the original text. For
further details on LMM see [33].
A SR is is a linear regression model with a single explanatory variable. It works by fitting a line through
the data that minimizes the sum of the squared of the residual, where the residuals are differences between
the observed values to the predicted values of the model. For example, when predicting the number of
interactions from the number co-administrations, the SR equation would look like
Φu(x) = β0 + β1x+ u (16)
where β0 is the intercept (or bias), β1 is the coefficient (or slope) and u are the residuals.
Similarly, PR is a regression where the dependent variable being modeled is fitted with a nth degree
polynomial, but still a single explanatory variable. In the main manuscript we modeled RRIy with a cubic
(3rd degree) polynomial. In our case, the PR equation would look like
RRIy(x) = β0 + β1(x3) + β2(x2) + β3x+ y (17)
where β0 is the intercept (or bias), β1, β2 and β3 are coefficients (giving the characteristic shape of the
cubic curve) and y are the residuals.
An OMR is a widely used type of regression for predicting the value of one dependent variable from the
value of a set of independent variables. Similar to SR, it works by fitting a hyperplane through the data
that minimizes the sum of the squared of the residuals.
In our case, the OMR equation would look like
Φu = β0 + β1xu,1 + β2xu,2 + ... βjxu,i + u (18)
Where β0 is the intercept (or bias), βj are the coefficients (or slopes) and each xu,i is a predictor (covariate,
regressor) such as age or number of drugs. u is the error associated with the fit.
A LMM (also known as multilevel, mixed effects, random effects or hierarchical linear model) can be seen
as extensions of the OMR where instances of the data belong to certain groups—like children in classrooms
or cities in states. In our case, they are patients in specific neighborhoods.
The individual levels are usually defined as level-1 (within-group), and level-2 (between-group) for a two
level model. Separate level-1 models (e.g., patients) are developed for each level-2 (e.g., neighborhoods).
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Considering only one predictor, level-1 models take the form of simple regressions:
Φu,n = β0,n + β1,nxu,n + ru,n (19)
where β0,n is the intercept for the n neighborhood, β1,n is a coefficient (slope) associated with predictor
xu,n, and ru,n is the error.
In the level-2 models, the level-1 regression coefficients (β0,n and β1,n) are used as outcome variables and
are related to each of the level-2 predictors.
β0,n = γ0,0 + γ0,1gn + u0,n (20)
β1,n = γ1,0 + γ1,1gn + u1,n (21)
where gn is the level-2 predictor, γ0,0 and γ1,0 are the overall mean intercept adjusted for g. γ0,1 (γ1,1)
is the regression coefficient associated with g relative to level-1 intercept (slope) and u0,n (u1,n) are level-2
random effects adjusted for g on the intercept (slope).
A combined two-level model is created by substituting Supplementary Equations 20 and 21 into Supple-
mentary Equation 19:
Φu,n = γ0,0 + γ1,0xu,n + γ0,1gn + γ1,1gnxu,n + u1,nx0,n + u0,n + u,n (22)
The combined model incorporates the level-1 and level-2 predictors (xu,n and gn), a cross-level term
(gnxu,n) as well as the composite error (u1,nxu,n + u0,n + ru,n).
In practice, LMM coefficients are estimated using maximum likelihood methods.
10.1 Simple Regression (SR) models
In Figure 3 of the main manuscript we show single regression models predicting the number of interactions.
Specifically, νu predicts Ψu best with a quadratic regression (R2 = .857) as shown in Figure 3-left. When
it comes to predicting number of interactions (Figure 3, center and right), on the other hand, there is
much more dispersion of the data, which leads to a relatively small linear correlation between Ψu and Φu
(R2 = .487)—though better than the linear correlation between νu and Φu (R2 = .304). However, higher
order regressions do not improve the prediction of the variance of Φu, as demonstrated by the Pareto front
in Fig. 3-top-right (see also Supplementary Note 11)—thus discarding the hypothesis of a clear nonlinear
relationship between co-administrations and interactions, which could explain the growth of RI with age.
Supplementary Tables below display additional regression models.
Listing 1: Ψu from νu linear model
===================================================
Ψu
νu 3.891*** (0.007)
Constant -8.818*** (0.037)
---------------------------------------------------
Observations 132 ,722
R2 0.712
Adjusted R2 0.712
Residual Std. Error 8.650 (df = 132720)
F Statistic 328 ,478.000*** (df = 1; 132720)
===================================================
Note: *p<0.1; **p <0.05; ***p<0.01
Listing 2: Ψu from νu quadratic model
===================================================
Ψu
νu -0.121*** (0.012)
(νu)2 0.273*** (0.001)
Constant -0.023 (0.036)
---------------------------------------------------
Observations 132 ,722
R2 0.857
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Adjusted R2 0.857
Residual Std. Error 6.088 (df = 132719)
F Statistic 399 ,075.300*** (df = 2; 132719)
===================================================
Note: *p<0.1; **p <0.05; ***p<0.01
Listing 3: Φu from νu linear model
==================================================
Φu
νu 0.110*** (0.0005)
Constant -0.267*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.304
Adjusted R2 0.304
Residual Std. Error 0.580 (df = 132720)
F Statistic 58 ,011.640*** (df = 1; 132720)
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
Listing 4: Φu from νu quadratic model
==================================================
Φu
νu -0.009*** (0.001)
(νu)2 0.008*** (0.0001)
Constant -0.007** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.372
Adjusted R2 0.372
Residual Std. Error 0.551 (df = 132719)
F Statistic 39 ,357.930*** (df = 2; 132719)
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
Listing 5: Φu from Ψu linear model
===================================================
Φu
Ψu 0.030*** (0.0001)
Constant -0.033*** (0.002)
---------------------------------------------------
Observations 132 ,722
R2 0.487
Adjusted R2 0.487
Residual Std. Error 0.498 (df = 132720)
F Statistic 126 ,232.900*** (df = 1; 132720)
===================================================
Note: *p<0.1; **p <0.05; ***p<0.01
10.1.1 RCy models
In Figure 2 of the main manuscript two regressions were calculated to predict the growth of RCy and RIy
based on age range (y = [y1 − y2]). Both RCy and RIy can be best approximated by a cubic polynomial
regression (see Fig. 2 for R2) The regression lines show different growth processes for co-administration and
interaction risks. RCy first decreases in children age range [5-14], followed by an almost flat level between
ages [15,44] before a steeper growth is observed for older age groups (see shaded area in Fig 2-left). In
contrast, RIy is initially quite flat and only starts to increase after the age of 15, after which it has a much
steeper growth curve than RC [y] (note the difference in scale).
In addition, Supplementary Tables below contain other regression models that were computed along with
their respective ANOVA comparison, when appropriate.
A linear model is the simplest model one could fit to the increased risk of co-administration.
Listing 6: RCy linear model
===============================================
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RCy
-----------------------------------------------
y 0.003*** (0.0004)
Constant 0.926*** (0.004)
-----------------------------------------------
Observations 19
R2 0.798
Adjusted R2 0.787
Residual Std. Error 0.009 (df = 17)
F Statistic 67.336*** (df = 1; 17)
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A quadratic model fits slightly better but the increased model complexity is not significant.
Listing 7: RCy quadratic model
===============================================
RCy
-----------------------------------------------
(y)2 0.0001 (0.0001)
y 0.001 (0.001)
Constant 0.931*** (0.005)
-----------------------------------------------
Observations 19
R2 0.820
Adjusted R2 0.798
Residual Std. Error 0.009 (df = 16)
F Statistic 36.493*** (df = 2; 16)
-----------------------------------------------
Model 1: RCy ~ y
Model 2: RCy ~ (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.0013609
2 16 0.0012139 1 0.00014698 1.9374 0.183
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A cubic model gives almost perfect fit while being significant for the more complex model.
Listing 8: RCy cubic model
===============================================
RCy
-----------------------------------------------
(y)3 -0.0001*** (0.00001)
(y)2 0.001*** (0.0003)
y -0.008*** (0.002)
Constant 0.943*** (0.004)
-----------------------------------------------
Observations 19
R2 0.936
Adjusted R2 0.923
Residual Std. Error 0.005 (df = 15)
F Statistic 72.789*** (df = 3; 15)
-----------------------------------------------
Model 1: RCy ~ y
Model 2: RCy ~ (y)2 + y
Model 3: RCy ~ (y)3 + (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.00136086
2 16 0.00121387 1 0.00014698 5.0807 0.0395787 *
3 15 0.00043394 1 0.00077993 26.9599 0.0001094 ***
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.1.2 RIy models
Similarly to how we modeled RIy, with the risk of known DDI co-administration (RIy) we start with the
simplest linear model possible.
Listing 9: RIy linear model
===============================================
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RIy
-----------------------------------------------
y 0.024*** (0.002)
Constant -0.032* (0.016)
-----------------------------------------------
Observations 19
R2 0.932
Adjusted R2 0.928
Residual Std. Error 0.037 (df = 17)
F Statistic 233.631*** (df = 1; 17)
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
A quadratic model fits slightly better but the increased model complexity is not significant.
Listing 10: RIy quadratic model
===============================================
RIy
-----------------------------------------------
(y)2 -0.0004 (0.0003)
y 0.030*** (0.006)
Constant -0.050** (0.023)
-----------------------------------------------
Observations 19
R2 0.937
Adjusted R2 0.930
Residual Std. Error 0.037 (df = 16)
F Statistic 119.823*** (df = 2; 16)
-----------------------------------------------
Model 1: RCy ~ y
Model 2: RCy ~ (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.023355
2 16 0.021550 1 0.001805 1.3401 0.264
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
Finally, a cubic model gives us almost perfect fit while being significant for the more complex model.
Listing 11: RIy Cubic model
===============================================
RIy
-----------------------------------------------
(y)3 -0.0003*** (0.00001)
(y)2 0.007*** (0.0004)
y -0.019*** (0.003)
Constant 0.013** (0.006)
-----------------------------------------------
Observations 19
R2 0.997
Adjusted R2 0.997
Residual Std. Error 0.008 (df = 15)
F Statistic 1 ,927.479*** (df = 3; 15)
-----------------------------------------------
Model 1: RIy ~ y
Model 2: RIy ~ (y)2 + y
Model 3: RIy ~ (y)3 + (y)2 + y
Res.Df RSS Df Sum of Sq F Pr(>F)
1 17 0.0233550
2 16 0.0215500 1 0.001805 30.391 5.96e-05 ***
3 15 0.0008909 1 0.020659 347.842 8.66e-12 ***
===============================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2 Multiple Regression (MR) models
This section displays several MR models that were generated in order to analyze the possible prediction
of drug interaction based on patient demographics. Tables below contain the model results and also their
respective ANOVA comparison when appropriate.
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10.2.1 Baseline (no transformation)
This is the baseline MR model with no transformation.
Listing 12: Baseline linear regression model
==================================================
Φu
--------------------------------------------------
νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
Constant 0.041*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.492
Adjusted R2 0.492
Residual Std. Error 0.496 (df = 132719)
F Statistic 64 ,377.810*** (df = 2; 132719)
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2.2 Baseline (transformed)
These are other baseline MR model with transformed variables
Listing 13: Transformed baseline MR model
==================================================
Φu
--------------------------------------------------
νu -0.004*** (0.001)
Ψu 0.040*** (0.0002)
(νu)2 -0.003*** (0.0001)
Constant -0.006** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.497
Adjusted R2 0.497
Residual Std. Error 0.493 (df = 132718)
F Statistic 43 ,696.240*** (df = 3; 132718)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + (νu)2
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132718 32304 1 288.37 1184.7 < 2.2e-16 ***
==================================================
Φu
--------------------------------------------------
νu -0.033*** (0.001)
Ψu 0.038*** (0.0002)
(Ψu)2 -0.00002*** (0.00000)
Constant 0.053*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.494
Adjusted R2 0.494
Residual Std. Error 0.495 (df = 132718)
F Statistic 43 ,145.430*** (df = 3; 132718)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + (Ψu)2
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132718 32508 1 84.745 345.99 < 2.2e-16 ***
==================================================
Φu
--------------------------------------------------
νu -0.008*** (0.001)
Ψu 0.041*** (0.0003)
(νu)2 -0.003*** (0.0001)
(Ψu)2 -0.00000*** (0.00000)
Constant 0.001 (0.003)
--------------------------------------------------
Observations 132 ,722
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R2 0.497
Adjusted R2 0.497
Residual Std. Error 0.493 (df = 132717)
F Statistic 32 ,786.680*** (df = 4; 132717)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + (νu)2 + (Ψu)2
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132717 32297 2 295.59 607.33 < 2.2e-16 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2.3 Baseline + age + gender
This section shows the MR results when age and gender are included as dependent variables in the baseline
model.
Listing 14: Baseline MR model added variables age and gender.
==================================================
Φu
--------------------------------------------------
νu -0.027*** (0.001)
Ψu 0.034*** (0.0002)
age 0.002*** (0.0001)
C(gender)Male -0.010*** (0.003)
Constant -0.021*** (0.004)
--------------------------------------------------
Observations 132 ,722
R2 0.496
Adjusted R2 0.496
Residual Std. Error 0.494 (df = 132717)
F Statistic 32 ,639.900*** (df = 4; 132717)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + age + C(gender)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132717 32369 2 223.56 458.33 < 2.2e-16 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2.4 Baseline (replacing Ψu with y)
Interestingly, number of co-administrations (Ψu) and age (y) are virtually exchangeable.
Listing 15: Baseline MR model exchanging variables Ψu and y.
==================================================
Φu
--------------------------------------------------
Ψu 0.029*** (0.0001)
age 0.002*** (0.0001)
Constant -0.100*** (0.003)
--------------------------------------------------
Observations 132 ,722
R2 0.491
Adjusted R2 0.491
Residual Std. Error 0.496 (df = 132719)
F Statistic 63 ,937.920*** (df = 2; 132719)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ Ψu + age
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132719 32702 0 -110.03
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
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10.2.5 Baseline + education level
This section shows the OMR results when education level is included as one of the dependent variables in
the model.
Note that this model fits a smaller dataset because the number of patients that have given their education
level is smaller than the full dataset.
Listing 16: Baseline MR model added education level variable.
================================================================
Φu
----------------------------------------------------------------
νu -0.015*** (0.001)
Ψu 0.033*** (0.0002)
C(education)Cant read/write -0.027** (0.014)
C(education)Complete college -0.007 (0.018)
C(education)Complete elementary 0.037*** (0.013)
C(education)Complete high school 0.003 (0.013)
C(education)Doctoral -0.106 (0.132)
C(education)Espec./ Residency 0.009 (0.045)
C(education)Incomplete college 0.004 (0.018)
C(education)Incomplete elementary 0.024** (0.011)
C(education)Incomplete high school -0.006 (0.014)
C(education)Masters -0.050 (0.119)
Constant 0.018 (0.011)
----------------------------------------------------------------
Observations 61 ,060
R2 0.511
Adjusted R2 0.511
Residual Std. Error 0.602 (df = 61047)
F Statistic 5 ,312.884*** (df = 12; 61047)
----------------------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + C(education)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 61057 22127
2 61047 22107 10 19.845 5.4801 3.472e-08 ***
================================================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2.6 Baseline + marital status
This section shows the OMR results when marital status is included as one of the dependent variables in the
model.
Listing 17: Baseline MR model added marital status variable.
=====================================================
Φu
-----------------------------------------------------
νu -0.027*** (0.001)
Ψu 0.035*** (0.0002)
C(marital)Divorced 0.105*** (0.025)
C(marital)Ignored -0.029*** (0.008)
C(marital)Married -0.005 (0.008)
C(marital)Not informed -0.072*** (0.008)
C(marital)Separated 0.080*** (0.011)
C(marital)Single -0.014* (0.008)
C(marital)Widower 0.019* (0.011)
Constant 0.077*** (0.008)
-----------------------------------------------------
Observations 132 ,722
R2 0.494
Adjusted R2 0.494
Residual Std. Error 0.495 (df = 132712)
F Statistic 14 ,420.090*** (df = 9; 132712)
-----------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + C(marital)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132712 32464 7 128.13 74.829 < 2.2e-16 ***
=====================================================
Note: *p <0.1; **p <0.05; ***p<0.01
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10.2.7 Baseline + average neighborhood income assigned to patients
Listing 18: Baseline MR model added average neighborhood income variable.
==================================================
Φu
--------------------------------------------------
νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
avg_income 0.00003*** (0.00000)
Constant 0.016*** (0.005)
--------------------------------------------------
Observations 132 ,722
R2 0.493
Adjusted R2 0.493
Residual Std. Error 0.495 (df = 132718)
F Statistic 42 ,944.890*** (df = 3; 132718)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + avg_income
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132718 32582 1 9.9727 40.622 1.853e-10 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2.8 Baseline + neighborhood safety variables assigned to patients
Listing 19: Baseline MR model added neighborhood safety variables.
==================================================
Φu
--------------------------------------------------
νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
theft_pc -0.737*** (0.283)
robbery_p1000 -0.004 (0.003)
suicide_p1000 0.006 (0.009)
transitcrime_p1000 0.022*** (0.002)
traffic_p1000 0.008*** (0.002)
rape_p1000 -0.002 (0.004)
Constant 0.024*** (0.004)
--------------------------------------------------
Observations 132 ,722
R2 0.493
Adjusted R2 0.493
Residual Std. Error 0.495 (df = 132713)
F Statistic 16 ,148.060*** (df = 8; 132713)
--------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + theft_pc +
robbery_p1000 + suicide_p1000 +
transitcrime_p1000 + traffic_p1000 +
rape_p1000
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132713 32538 6 54.096 36.773 < 2.2e-16 ***
==================================================
Note: *p <0.1; **p <0.05; ***p <0.01
10.2.9 Baseline + neighborhood
Listing 20: Baseline MR model added neighborhood as categorical variables.
======================================================
Φu
------------------------------------------------------
νu -0.026*** (0.001)
Ψu 0.035*** (0.0002)
C(hood)BADENFURT -0.021 (0.014)
C(hood)BOA VISTA 0.009 (0.024)
C(hood)BOM RETIRO 0.150*** (0.036)
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C(hood)CENTRO 0.012 (0.013)
C(hood)DA GLORIA -0.009 (0.013)
C(hood)DO SALTO -0.005 (0.016)
C(hood)ESCOLA AGRICOLA -0.041*** (0.012)
C(hood)FIDELIS 0.005 (0.013)
C(hood)FORTALEZA -0.030*** (0.011)
C(hood)FORTALEZA ALTA -0.029** (0.014)
C(hood)GARCIA -0.009 (0.011)
C(hood)ITOUPAVA CENTRAL 0.005 (0.011)
C(hood)ITOUPAVA NORTE -0.023** (0.011)
C(hood)ITOUPAVA SECA -0.037** (0.019)
C(hood)ITOUPAVAZINHA 0.012 (0.012)
C(hood)JARDIM BLUMENAU -0.053 (0.047)
C(hood)NOVA ESPERANCA -0.055*** (0.014)
C(hood)OTHER -0.067*** (0.010)
C(hood)PASSO MANSO 0.025* (0.015)
C(hood)PONTA AGUDA -0.009 (0.013)
C(hood)PROGRESSO -0.006 (0.011)
C(hood)RIBEIRAO FRESCO 0.010 (0.021)
C(hood)SALTO DO NORTE 0.019 (0.015)
C(hood)SALTO WEISSBACH 0.018 (0.018)
C(hood)TESTO SALTO -0.009 (0.015)
C(hood)TRIBESS -0.041*** (0.012)
C(hood)VALPARAISO -0.015 (0.014)
C(hood)VELHA -0.015 (0.011)
C(hood)VELHA CENTRAL -0.009 (0.013)
C(hood)VELHA GRANDE -0.031* (0.017)
C(hood)VICTOR KONDER 0.026 (0.024)
C(hood)VILA FORMOSA -0.225*** (0.053)
C(hood)VILA ITOUPAVA 0.015 (0.017)
C(hood)VILA NOVA -0.041*** (0.015)
C(hood)VORSTADT -0.028** (0.014)
Constant 0.067*** (0.010)
------------------------------------------------------
Observations 132 ,722
R2 0.494
Adjusted R2 0.494
Residual Std. Error 0.495 (df = 132684)
F Statistic 3 ,502.150*** (df = 37; 132684)
------------------------------------------------------
Model 1: Φu ~ νu + Ψu
Model 2: Φu ~ νu + Ψu + C(hood)
Res.Df RSS Df Sum of Sq F Pr(>F)
1 132719 32592
2 132684 32486 35 106.61 12.441 < 2.2e-16 ***
======================================================
Note: *p<0.1; **p <0.05; ***p<0.01
10.3 Linear Mixed-Effect (LMM) models
To be sure there were not nested effects between variables gender and age, we also ran a linear mixed-model
(LMM) where variable gender is nested within age. This model accounts for specific differences within patient
age and across different genders. Intuitively, if there are large variations in the number of interaction that
are explained by the nestedness of gender and age, these groups would help explain a large portion of the
variance in the data. The results indicate that is not the case. In fact, the variance attributed to gender
(within age) group is 0.00016 while the age group is a little higher, 0.00217.
Listing 21: Linear Mixed Model with age nested within gender.
Linear mixed model fit by maximum likelihood [’lmerMod ’]
ForFormula: Φu ~ νu + Ψu + (1 | age/gender)
Data: data
AIC BIC logLik deviance df.resid
189314.1 189372.9 -94651.1 189302.1 132716
Scaled residuals:
Min 1Q Median 3Q Max
-13.1102 -0.2048 -0.0734 0.0394 19.2402
Random effects:
Groups Name Variance Std.Dev.
gender:age (Intercept) 0.0001645 0.01282
age (Intercept) 0.0021678 0.04656
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Residual 0.2432636 0.49322
Number of obs: 132722 , groups: gender:age , 213; age , 109
Fixed effects:
Estimate Std. Error t value
(Intercept) 0.0483215 0.0055929 8.64
νu -0.0262493 0.0007287 -36.02
Ψu 0.0343219 0.0001590 215.87
Correlation of Fixed Effects:
(Intr) νu
νu -0.367
Ψu 0.224 -0.831
To be sure that neighborhood did not differ in their DDI observations, we also ran a linear mixed-model
(LMM) with neighborhood as a random effect. Intuitively, if there are variations in the number of interactions
between neighborhoods that cannot be explained by the independent variables alone—due to, say, differences
in policies or practices—we should see the random effect variable explaining a great deal of the variance in
the model. Our results indicate that is not the case. In fact, the variance attributed to the neighborhood
random effect is 0.00059 and therefore too small. This shows that at least in predicting the number of DDI,
there is neighborhood homogeneity in how they are being prescribed and thus dispensed.
Listing 22: Linear Mixed Model with neighborhood as random effect.
Linear mixed model fit by maximum likelihood [’lmerMod ’]
Formula: Φu ~ νu + Ψu + (1 | hood)
Data: data
AIC BIC logLik deviance df.resid
189980.7 190029.6 -94985.3 189970.7 132717
Scaled residuals:
Min 1Q Median 3Q Max
-13.1462 -0.1846 -0.0678 0.0180 19.1046
Random effects:
Groups Name Variance Std.Dev.
hood (Intercept) 0.0005935 0.02436
Residual 0.2448642 0.49484
Number of obs: 132722 , groups: hood , 36
Fixed effects:
Estimate Std. Error t value
(Intercept) 0.0544948 0.0050850 10.72
νu -0.0264618 0.0007270 -36.40
Ψu 0.0348255 0.0001572 221.58
Correlation of Fixed Effects:
(Intr) νu
νu -0.411
Ψu 0.268 -0.841
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Supplementary Note 11 Patient classification
We applied machine learning classifiers in order to predict if a specific patient had at least one DDI in
the whole 18 month period. A binary classification task. Support Vector Machine (SVM)[34] and Logis-
tic Regression (LR)[35] are considered both standard and reliable machine learning algorithm for binary
classification problems. We built models for each classifier considering different sets of features, including
demographic (i.e., age & gender) and drugs the patient was prescribed in the period. For baseline comparison
we also ran against three null model classifiers. One with a “coin-toss” probability of classification (Uniform),
another with a bias with respect to class probability (Biased), and a custom made (AgeGender) which finds
the best age cutoff for each gender from which it consider all patients older than the cutoff as having a DDI.
Regression and classification models were computed using R and Python [36].
We present results as measures derived from a confusion matrix, also called a contingency table[37]. The
confusion matrix contains four categories: true positives (TP ), patients correctly labeled as having a DDI;
false positives (FP ), patients incorrectly classified as having a DDI; true negative (TN), patients correctly
labeled as not having a DDI; and finally false negatives (FN), patients with DDI but mislabeled as not
having them. A contingency table example can be seen in Table 36.
From the confusion matrix we compute Precision and Recall as
Precision =
TP
TP + FP
, Recall =
TP
TP + FN
, (23)
where Precision is the fraction of patients with DDI correctly predicted, among all predicted patients with
DDI; while Recall is the fraction of patients with DDI correctly predicted, among all patients with DDI. We
also compute True Positive Rate (TPR) and False Positive Rate (FPR) measures as
TPR =
TP
TP + FN
, FPR =
FP
FP + TN
, (24)
where TPR measures the fraction of patients with DDI that are correctly classified and FPR measures
the fraction of patients with no DDI incorrectly classified as having DDI. These four measures enables the
plotting of the Receiver Operator Characteristic (ROC) and the Precision and Recall (P/R) space. In ROC
space we plot FPR against TPR while in P/R space we plot Precision against Recall (Figure 15 displays the
results). These plots are typically generated to evaluate the performance of machine learning algorithms,
and to enable system users to inspect the trained algorithm’s precision at a specific recall level, for example.
From both ROC and P/R curves we computes their respective interpolated area under the curve (AUC)[37].
From Precision and Recall we also compute the F1-score (also called F -score or F -measure) as
F1 = 2× Precision× RecallPrecision + Recall . (25)
We also compute Matthew’s Correlation Coefficient (MCC)[38], which is regarded as an ideal measure of
the quality of binary classification in unbalanced scenarios[39], as
MCC =
TP × TN − FP × FN√
(TP + FP ) + (TP + FN) + (TN + FP ) + (TN + FN)
. (26)
Below, we display results as measures of Precision, Recall, F1-score, MCC, AUC ROC curve and AUC
P/R curve.
We also display the full table of feature weights for both classifiers. Since these are both linear classifiers,
DDI no DDI
predicted DDI TP FP
predicted no DDI FN TN
Supplementary Table 36: Confusion Matrix.
52
one can interpret positive (negative) values as contributing to the positive (negative) class—having a DDI.
The higher (smaller) the weight, the bigger (smaller) the contribution. All results are based on 4-fold cross
validation.
† Gender is used as a categorical variable and expanded into the binary features (g = M and g = F ).
‡ Education level is used as a categorical variable expanded into individuals binary features (“Cant read/write”, “Can read/write
a note”, “Incomplete elementary”, “Complete elementary”, “Incomplete high school”, “Complete high school”, “Incomplete college”,
“Complete college”, “Espec./Residency”, “Masters”, and “Doctoral”).
11.1 Simple model
Patients: 132,722
DDI (positive): 15,527 (11.70%)
no DDI (negative): 117,195 (88.30%)
Features: 127
Demographic: gender† (g), age (y), number of drugs (νu), number of co-administrations (Ψu).
Neighborhood: average income, number of thefts per capita, number of robberies per capita, number
of suicides per capita, number of transit crimes per capita, number of traffic accidents per capita,
number of rapes per capita.
Drug: all drugs D.
Fold Precision Recall F1 MCC AUC ROC AUC P/R
1 0.8196 0.6309 0.7130 0.6877 0.9676 0.8269
2 0.8241 0.6494 0.7264 0.7011 0.9702 0.8365
3 0.8127 0.6504 0.7226 0.6957 0.9697 0.8315
4 0.8187 0.6436 0.7207 0.6949 0.9690 0.8311
Mean 0.8188 0.6436 0.7207 0.6948 0.9691 0.8315
Supplementary Table 37: Individual fold and mean performance of Support Vector Machine (SVM) classifier on stratified 4-
fold cross-validation, using demographic and drug features. Measures of performance shown are: Precision, Recall, F1 (balanced
Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and
the Area Under the Precision and Recall Curve.
Fold Precision Recall F1 MCC AUC ROC AUC P/R
1 0.8085 0.6535 0.7228 0.6953 0.9675 0.8249
2 0.8096 0.6669 0.7314 0.7037 0.9700 0.8337
3 0.7991 0.6662 0.7266 0.6977 0.9697 0.8299
4 0.8092 0.6612 0.7277 0.7002 0.9691 0.8304
Mean 0.8066 0.6619 0.7271 0.6992 0.9691 0.8297
Supplementary Table 38: Individual fold and mean performance of Logistic Regression (LR) classifier on stratified 4-fold
cross-validation, using demographic and drug features. Measures of performance shown are: Precision, Recall, F1 (balanced
Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and
the Area Under the Precision and Recall Curve.
11.2 Complete model
Patients: 132,722
DDI (positive): 15,527 (11.70%)
no DDI (negative): 117,195 (88.30%)
Features: 154
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Classifier Precision Recall F1 MCC AUC ROC AUC P/R
Uniform 0.1181 0.5075 0.1916 0.0035 0.5 0.5585
Biased 0.1147 0.1153 0.1150 -0.0026 0.4987 0.1668
GenderAge 0.2044 0.8834 0.3320 0.2751 0.7139 0.5507
Supplementary Table 39: Mean performance of Uniform (coin-toss), Biased (biased coin-toss on class distribution) and
GenderAge (hard cutoff for gender and gender) classifiers on stratified 4-fold cross-validation, using demographic and drug
features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation
Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.
Demographic: gender† (g), age (y), number of drugs (νu), number of co-administrations (Ψu), edu-
cation levels‡.
Neighborhood: average income, number of thefts per capita, number of robberies per capita, number
of suicides per capita, number of transit crimes per capita, number of traffic accidents per capita,
number of rapes per capita.
Drug: all drugs D.
Classifier Precision Recall F1 MCC AUC ROC AUC P/R
SVM 0.8186 0.6442 0.7210 0.6951 0.9690 0.8312
LR 0.8070 0.6619 0.7273 0.6994 0.9690 0.8295
Supplementary Table 40: Mean performance of classifiers on stratified 4-fold cross-validation, using all possible features,
including demographic, neighborhood and drugs dispensed. Measures of performance shown are: Precision, Recall, F1 (balanced
Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and
the Area Under the Precision and Recall Curve.
11.3 No Drugs model
This model is similar to the “simple” model, except no drug features are used.
Patients: 132,722
DDI (positive): 15,527 (11.70%)
no DDI (negative): 117,195 (88.30%)
Features: 5
Demographic: gender† (g), age (y), number of drugs (νu), number of co-administrations (Ψu).
Neighborhood: None.
Drug: None.
Classifier Precision Recall F1 MCC AUC ROC AUC P/R
SVM 0.7578 0.3791 0.5053 0.4971 0.9185 0.6539
LR 0.7172 0.4170 0.5273 0.5044 0.9130 0.6391
Supplementary Table 41: Mean performance of classifiers on stratified 4-fold cross-validation, using only demographic
features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation
Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.
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11.4 Precision & Recall and Receiver Operating Characteristic curves
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Supplementary Figure 15: Precision and Recall (P/R) curve and Receiver operating characteristic (ROC) curve for indi-
vidual cross-validation folds. Model containing demographic and drug features. Black and green dotted line shows the baseline
and mean values, respectively.
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11.5 Feature loadings
Supplementary Tables 42 and 43 shows the feature loading for both SVM and LR classifiers on model
“simple”.
feature coef feature coef
d=Digoxin 1.1677 d=Acetaminophen -0.1169
d=Diltiazem 0.8718 d=Tobramycin -0.1185
d=Warfarin 0.6938 d=Hydrochlorothiazide -0.1203
d=Haloperidol 0.6879 d=Norethisterone -0.1225
d=Glyburide 0.6681 d=Propylthiouracil -0.1242
d=Pyrimethamine 0.6549 d=Phenylephrine -0.1309
d=Phenytoin 0.6015 d=Estrogens Conjugated -0.1312
d=Biperiden 0.5807 d=Trimethoprim -0.1325
d=Carbamazepine 0.5752 d=Sulfamethoxazole -0.1325
d=Gliclazide 0.4735 d=Colchicine -0.1333
d=Clonazepam 0.4717 d=Diclofenac -0.1347
d=Methyldopa 0.4617 d=Ranitidine -0.1374
d=Propranolol 0.4487 d=Neomycin -0.1383
d=Lithium 0.3887 d=Bacitracin -0.1383
d=Fluconazole 0.3716 d=Nimesulide -0.1413
νi 0.3169 d=Fenoterol -0.1446
d=Acetylsalicylic Acid 0.3119 d=Nystatin -0.1508
Ψi,j 0.3080 d=Albendazole -0.1514
d=Diazepam 0.3038 d=Nitrofurantoin -0.1514
d=Omeprazole 0.2822 d=Loratadine -0.1611
d=Amitriptyline 0.2810 d=Metamizole -0.1624
d=Iron (II) Sulfate 0.2584 d=Spironolactone -0.1634
d=Ethinyl Estradiol 0.2571 d=Tramadol -0.1643
d=Ibuprofen 0.2170 d=Dexchlorpheniramine maleate -0.1664
d=Imipramine 0.1825 d=Enalapril -0.1671
d=Fluoxetine 0.1639 d=Azithromycin -0.1672
d=Verapamil 0.1455 d=Miconazole -0.169
d=Timolol 0.1452 d=Scopolamine butylbromide -0.171
d=Atenolol 0.1432 d=Metronidazole -0.1747
d=Nortriptyline 0.1159 d=Cephalexin -0.1767
d=Doxycycline 0.1046 d=Ipratropium Bromide -0.1779
d=Nifedipine 0.0973 d=Hydrocortisone -0.1812
d=Methylphenidate 0.0638 d=Metoclopramide -0.1832
d=Vaseline 0.0596 d=Levodopa -0.1872
y 0.0518 d=Medroxyprogesterone Acetate -0.1877
d=Phenobarbital 0.0274 d=Doxazosin -0.1909
d=Prednisone 0.0232 d=Amlodipine -0.1936
d=Estradiol 0.0181 d=Losartan -0.1937
d=Atropine 0.0000 d=Metformin -0.1943
d=Thiocolchicoside 0.0000 d=Mebendazole -0.1945
d=Salbutamol -0.0071 d=Fluphenazine -0.204
d=Dexamethasone -0.0102 d=Captopril -0.2041
d=Penicillin G procaine -0.0115 d=Amiodarone -0.2042
d=Simvastatin -0.0191 d=Bromazepam -0.2063
d=Gentamicin -0.0229 d=Codeine -0.2064
d=Epinephrine -0.0347 d=Valproic acid -0.2083
d=Furosemide -0.0395 d=Penicillin G Benzathine -0.2123
d=Carvedilol -0.0544 d=Aminophylline -0.2133
d=Erythromycin -0.0588 d=Clavulanate -0.2141
d=Chlorpromazine -0.0605 d=Clopidogrel -0.2162
d=Methotrimeprazine -0.0683 d=Carbidopa -0.2269
d=Morphine -0.0759 d=Insulin -0.246
d=Levothyroxine -0.0776 d=Isosorbide Mononitrate -0.269
d=Alendronate -0.0820 d=Nicotine -0.3003
d=Amoxicillin -0.0908 d=Glucose -0.305
d=Ciprofloxacin -0.0937 g = M -0.3193
d=Prednisolone -0.0944 g = F -0.3213
d=Permethrin -0.0978 d=Sodium chloride -0.3474
d=Levonorgestrel -0.0982 d=Isosorbide Dinitrate -0.351
d=Folic acid -0.0983 d=Oseltamivir -0.3643
d=Promethazine -0.1059 d=Betamethasone -0.4765
d=Maprotiline -0.1073 d=Spiramycin -0.521
d=Norfloxacin -0.1100 d=Sulfadiazine -0.5259
d=Allopurinol -0.1148 - -
Supplementary Table 42: Feature weights for Support Vector Machine (SVM) classifier on model “simple”.
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feature coef feature coef
d=Digoxin 3.6826 d=Norethisterone -0.4217
d=Diltiazem 2.7678 d=Amoxicillin -0.4283
d=Haloperidol 2.3874 d=Promethazine -0.4327
d=Warfarin 2.3423 d=Colchicine -0.434
d=Glyburide 2.2139 d=Hydrochlorothiazide -0.4526
d=Phenytoin 2.1363 d=Norfloxacin -0.4545
d=Carbamazepine 2.1098 d=Estrogens Conjugated -0.4683
d=Biperiden 1.9247 d=Tobramycin -0.4763
d=Clonazepam 1.6984 d=Propylthiouracil -0.4767
d=Methyldopa 1.6363 d=Trimethoprim -0.4888
d=Propranolol 1.5735 d=Sulfamethoxazole -0.4888
d=Gliclazide 1.5618 d=Acetaminophen -0.502
νi 1.4941 d=Spiramycin -0.506
d=Fluconazole 1.3668 d=Ranitidine -0.5178
d=Lithium 1.3303 d=Diclofenac -0.5242
d=Acetylsalicylic Acid 1.0479 d=Betamethasone -0.5301
d=Diazepam 1.0178 d=Nimesulide -0.5316
d=Omeprazole 1.0114 d=Neomycin -0.5318
d=Amitriptyline 0.9684 d=Bacitracin -0.5318
d=Iron (II) Sulfate 0.8905 d=Nystatin -0.5508
Ψi,j 0.7721 d=Prednisolone -0.5531
d=Ibuprofen 0.7282 d=Fenoterol -0.5542
d=Pyrimethamine 0.6518 d=Spironolactone -0.564
d=Fluoxetine 0.6245 d=Hydrocortisone -0.5778
d=Imipramine 0.6188 d=Mebendazole -0.5857
d=Atenolol 0.5100 d=Enalapril -0.5955
d=Ethinyl Estradiol 0.4965 d=Albendazole -0.5991
d=Verapamil 0.3885 d=Nitrofurantoin -0.6128
d=Doxycycline 0.3681 d=Miconazole -0.6173
y 0.3547 d=Ipratropium Bromide -0.619
d=Timolol 0.3492 d=Loratadine -0.6196
d=Nortriptyline 0.3217 d=Metamizole -0.6206
d=Nifedipine 0.2797 d=Scopolamine butylbromide -0.6347
d=Levonorgestrel 0.2220 d=Tramadol -0.6364
d=Phenobarbital 0.1465 d=Metronidazole -0.6476
d=Vaseline 0.1118 d=Dexchlorpheniramine maleate -0.6534
d=Estradiol 0.0873 d=Medroxyprogesterone Acetate -0.6733
d=Prednisone 0.0824 d=Metformin -0.6762
d=Epinephrine 0.0357 d=Azithromycin -0.6796
d=Erythromycin 0.0242 d=Captopril -0.6855
d=Thiocolchicoside -0.0044 d=Losartan -0.6882
d=Atropine -0.0128 d=Amlodipine -0.6899
d=Sulfadiazine -0.0250 d=Cephalexin -0.6901
d=Penicillin G procaine -0.0593 d=Doxazosin -0.6929
d=Salbutamol -0.0845 d=Metoclopramide -0.7212
d=Phenylephrine -0.0869 d=Aminophylline -0.7297
d=Simvastatin -0.0914 d=Codeine -0.7311
d=Dexamethasone -0.0917 d=Clopidogrel -0.7375
d=Gentamicin -0.1000 d=Amiodarone -0.7402
d=Methylphenidate -0.1019 d=Clavulanate -0.7449
d=Sodium chloride -0.1856 d=Valproic acid -0.7461
d=Fluphenazine -0.2091 d=Carbidopa -0.7552
d=Furosemide -0.2152 d=Bromazepam -0.7571
d=Methotrimeprazine -0.2171 d=Levodopa -0.7619
d=Carvedilol -0.2223 d=Penicillin G Benzathine -0.8072
d=Chlorpromazine -0.2356 d=Insulin -0.8443
d=Maprotiline -0.2791 d=Isosorbide Mononitrate -0.9186
d=Morphine -0.2889 d=Nicotine -0.9342
d=Levothyroxine -0.2929 d=Glucose -0.9742
d=Folic acid -0.3650 g = M -1.116
d=Alendronate -0.3683 g = F -1.132
d=Allopurinol -0.3954 d=Isosorbide Dinitrate -1.178
d=Permethrin -0.4101 d=Oseltamivir -1.3
d=Ciprofloxacin -0.4119 - -
Supplementary Table 43: Feature weights on Logistic Regression (LR) classifier on model “simple”.
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